CLINICAL STUDY PROTOCOL  
 
 
Unique Protocol ID: CB8025-31735 
 
 
Official Title: A 52 -week, placebo -controlled, randomized, Phase 3 study to  evaluate the safety 
and efficacy of seladelpar in subjects with  primary biliary cholangitis (PBC) and an inadequate 
response  to or an intolerance to ursodeoxycholic acid (UDCA)  
 
NCT number: [STUDY_ID_REMOVED] 
 
Protocol Version Number: Version 1.0 
 
Date : 3-JUL-2018 
CymaBay Therapeutics, Inc  Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL Page 1 of 94 CB8025-31735 
PROTOCOL TITLE:  A 52-week, placebo -controlled, randomized, Phase 3 study to 
evaluate the safety and efficacy of seladelpar  in subjects with 
primary biliary c holangitis (PBC) and an inadequate response 
to or an intolerance to ursodeoxycholic acid (UDCA)  
PROTOCOL  
VERSION NUMBER:  Version 1.0 
DATE OF PROT OCOL:  3- JUL-2018
PROTOCOL NUMBER:  CB8025-31735 
SPONSOR:  CymaBay Therapeutics, Inc. 
7575 Gateway Blvd, Suite 110 
Newark, CA 94560 
United States of America  
SPONSOR CONTACT:   
EudraCT number: 2018-001171-20 
CONFIDENTIALITY STATEMENT  
This document contains confidential information, which should not be disclosed, copied, referred to, released or 
published without writte n approval from CymaBay Therapeutics . Any su pplemental information that may be 
added to this document is also confidential and  proprietary to CymaBay Therapeutics  and must be kept in 
confidence in the same manner as the contents of this document.  

CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 3 of 94 TABLE OF CONTENT S 
1 LIST OF ABBREVIATION S ..................................................................................7  
2 LIST OF SPONSOR CONTACTS  ..........................................................................9  
3 SYNOPSIS  .............................................................................................................10  
4 INTRODUCTION  .................................................................................................27  
4.1 Primary Biliary Cholangitis (PBC)  ..................................................................27  
4.2 Seladelpar  .........................................................................................................28  
4.2.1  Overview  ..............................................................................................28  
4.2.2  Mechanism of Action  ...........................................................................28  
4.3 Nonclinical Investigations with Seladelpar  .....................................................28  
4.4 Human Experience  ...........................................................................................28  
4.4.1  Phase 1 Studies ....................................................................................29  
4.4.2  Phase 2 Studies in PBC Patients  ..........................................................29  
4.4.3  Phase 2 Studies in Non- PBC Patients  ..................................................31  
4.5 Risk/Benefit Assessment  .................................................................................31  
4.5.1  Potential Benefits  .................................................................................31  
4.5.2  Potential Risks  .....................................................................................32  
4.5.2.1  Non-clinical Safety Findings  ......................................................32  
4.5.2.2  Human Safety ..............................................................................32  
4.6 Rationale for Dose Selection  ...........................................................................33  
4.7 Conclusions ......................................................................................................33  
5 STUDY OBJECTIVES  ..........................................................................................34  
5.1 Primary Objectives ...........................................................................................34  
5.2 Secondary Objectives .......................................................................................34  
5.3 Exploratory Objectives ....................................................................................34  
6 STUDY POPULATION  ........................................................................................35  
6.1 Selection Criteria  .............................................................................................35  
6.1.1  Inclusion Criteria  .................................................................................35  
6.1.2  Exclusion Criteria  ................................................................................35  
7 STUDY DESIGN ...................................................................................................37  
7.1 Treatment and Allocation of Subjects ..............................................................38  
7.2 Study Duration  .................................................................................................39  
7.3 Study Outcome Measurements ........................................................................39  
7.3.1  Primary Measures  ................................................................................39  
7.3.2  Key Secondary Measures  .....................................................................39  
7.3.3  Other Secondary Measures  ..................................................................39  
7.3.4  Exploratory Measures  ..........................................................................40  
8 STUDY MEDICATIONS  ......................................................................................41  
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 4 of 94 8.1 Clinical Supplies  ..............................................................................................41  
8.1.1  Investigational Product (Study Drug), Dosage and Mode of 
Administration  .....................................................................................41  
8.1.2  UDCA, Dosage and Mode of Administration......................................41  
8.1.3  Packaging, Labeling and Shipping  ......................................................41  
8.1.3.1  Dose Up -titration  ........................................................................41  
8.1.3.2  Dose Down -titration ....................................................................41  
8.1.4  Accountability of C linical Supplies  .....................................................41  
8.1.5  Replacement Study Drug and UDCA  ..................................................42  
8.1.6  Storage of Study Drug and UDCA  ......................................................42  
8.2 Randomization .................................................................................................42  
8.2.1  Randomization Procedure ....................................................................42  
8.3 Emergency Unblinding ....................................................................................42  
8.4 Method of Administration and Compliance ....................................................42  
8.5 Concomitant Medications and Procedures.......................................................42  
8.5.1  Concomitant Medications  ....................................................................43  
8.5.1.1  Allowed Concomitant Medication: .............................................43  
8.5.1.2  Prohibited Concomitant Medication ...........................................43  
8.5.2  Concomitant P rocedures  ......................................................................43  
9 STUDY PROCEDURES  .......................................................................................44  
9.1 Study Schedule.................................................................................................44  
9.1.1  Screening (Week -4 to Week -2) .........................................................44  
9.1.2  Run- In (Week -2 to Day 1) ..................................................................45  
9.1.3  Treatment Period  ..................................................................................46  
9.1.4  Post- Treatment Follow -Up ..................................................................52  
9.1.5  Early Termination Visit .......................................................................52  
9.1.6  Unscheduled Visit ................................................................................53  
9.2 Study Assessments  ...........................................................................................53  
9.2.1  Medical History and Physi cal Examination  .........................................53  
9.2.2  Vital Signs and Weight/Height  ............................................................54  
9.2.3  Electrocardiograms  ..............................................................................54  
9.2.4  Laboratory Tests  ..................................................................................54  
9.2.5  Liver Elastography  ...............................................................................55  
9.2.6  Liver Biopsy.........................................................................................56  
9.2.7  Pruritus Numerical Rating Scale (NRS)  ..............................................56  
9.2.8  5-D Itch Scale  ......................................................................................56  
9.2.9  PBC -40 QoL ........................................................................................57  
9.2.10  PGI-S and PGI-C .................................................................................57  
9.3 Dose Titration  ..................................................................................................57  
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 5 of 94 10 ADVERSE EVENTS  .............................................................................................58  
10.1  General  .............................................................................................................58  
10.1.1  Definition of Adverse Events...............................................................58  
10.1.2  Definition of Serious AEs (SAEs) .......................................................58  
10.1.3  AE Severity  ..........................................................................................58  
10.1.4  Adverse Event Outcome ......................................................................59  
10.1.5  Relationship to Study Drug ..................................................................59  
10.1.6  Action Taken with Study Medication ..................................................60  
10.2  Recording, Reporting, and Follow-up of Adverse Events ...............................60  
10.2.1  SAE Reporting Process ........................................................................61  
10.2.2  Follow-up of Repor ted AEs  .................................................................62  
10.3  Distribution of Responsibilities  .......................................................................62  
10.4  Safety Monitoring Criteria and Withdrawal Criteria  .......................................62  
10.4.1  Liver Safety Monitoring ......................................................................62  
10.4.2  Muscle Safety Monitoring ...................................................................63  
10.4.3  Serum Creatinine Monitoring ..............................................................64  
10.4.4  Pancreatic Saf ety Monitoring ..............................................................64  
10.4.5  Additional Withdrawal Criteria and Replacement of Subjects  ............64  
10.5  Precautions  .......................................................................................................65  
10.5.1  Pregnancy  .............................................................................................65  
11 STUDY TERMINATION .....................................................................................66  
12 DATA HANDLING CONSIDERATIONS  ...........................................................67  
12.1  Processing of Electronic Case Report Forms ...................................................67  
12.2  Database  ...........................................................................................................67  
12.3  Data Discrepancies ...........................................................................................67  
13 STATISTICAL ANALYSES  ................................................................................68  
13.1  General Statistical Considerations  ...................................................................68  
13.2  Determination of Sample Size  .........................................................................68  
13.3  Analysis Sets  ....................................................................................................69  
13.3.1  Safety Set  .............................................................................................69  
13.3.2  Intent to Treat Analysis Set (ITT)  ........................................................69  
13.3.3  Modi fied Intent to Treat Analysis Set  ..................................................69  
13.3.4  Per Protocol (PP) Analysis Set  ............................................................69  
13.4  Analysis Time Points  .......................................................................................69  
13.5  Handling of Drop-Outs and Missing Data .......................................................69  
13.6  Disp osition, Demographics and Baseline Characteristics  ...............................70  
13.7  Efficacy Analysis  .............................................................................................70  
13.8  Safety Analysis  ................................................................................................73  
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 6 of 94 14 DIRECT ACCESS TO SOU RCE DATA/DOCUMENTS  ....................................74  
14.1  Study Monitoring .............................................................................................74  
14.1.1  Source Documents ...............................................................................74  
14.1.2  Case Report Forms  ...............................................................................74  
14.1.3  Protocol Deviations ..............................................................................74  
14.2  Audits and Inspections .....................................................................................74  
14.2.1  Trial Auditing .......................................................................................74  
14.2.2  Trail Monitoring ...................................................................................74  
14.3  Ethics Committees  ...........................................................................................75  
15 QUALITY CONTROL AND QUALITY ASSURANCE  .....................................76  
16 ETHICS ..................................................................................................................77  
16.1  Ethics Review  ..................................................................................................77  
16.2  Ethical Conduct of the Study ...........................................................................77  
16.3  Written Informed Consent ...............................................................................77  
17 RETENTION OF RECORDS  ...............................................................................78  
18 PROTOCOL AMENDMENTS  .............................................................................79  
19 DISCLOSURE OF INFORMATION AND PUBLICATION POLICY  ...............80  
20 REFERENCES  ......................................................................................................81  
 
 
LIST OF TABLES  
Table 1  Schedule of Assessments  ...........................................................................25  
 
LIST OF FIGURES  
Figure  1 Mean Percent Changes in AP in PBC Phase 2 S tudies  ..............................30  
Figure  2 Median Percent Change in ALT in PBC Phase 2 Studies .........................30  
Figure  3 Study Diagram – Clinical Study CB8025-31735.......................................38  
 
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 7 of 94 1 LIST OF ABBREVIATION S 
AE Adverse e vent 
ALT  Alanine aminotransferase  
AMA  Anti-mitochondrial a ntibodies  
ANCOVA  Analysis of covariance  
AP Alkaline p hosphatase  
AST  Aspartate a minotransferase  
BA Bile acids  
BMI  Body mass index  
BUN  Blood urea n itrogen  
C4 7α-hydroxy -4-cholesten -3-one 
CDCA  Chenodeoxycholic acid  
CERC  Critical Event Review Committee  
CFR  Code of Federal Regulations  
CK Creatine  kinase  
CMH  Cochran -Mantel -Haenszel  
CRA  Clinical Research Associate  
CRO  Contract Research Organization  
CTCAE  Common Terminology Criteria for Adverse Events  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
EDC  Electronic data capture  
eGFR  Estimated glomerular filtration r ate 
ELF Enhanced liver fibrosis  
ELISA  Enzyme linked immunosorbent assay  
FGF19  Fibroblast growth factor 19  
FIB-4 Fibrosis -4 
GCP  Good Clinical Practice  
GGT  Gamma -glutamyl t ransferase  
HA Hyaluronic acid  
HBsAg  Hepatitis B Surface Antigen  
HCV  Hepatitis C Virus  
HDL -C High density lipoprotein c holesterol  
HoFH  Homozygous familial h ypercholesterolemia  
hs-CRP  High sensitivity C -reactive protein  
IB Investigator ’s brochure  
ICF Informed consent f orm 
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use  
IEC Independent ethics committee  
IgM Immunoglobulin M  
INR International n ormalized ratio 
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 8 of 94 ITT Intent to t reat 
IXRS  Interactive voice/web response system  
LDH  Lactate d ehydrog enase  
LDL -C  Low density lipoprotein c holesterol  
LOCF  Last observation carried f orward  
M1, M2, M3  Seladelpar (MBX -8025) m etabolites  
MBX -8025  Seladelpar  
MedRA  Medical Dictionary for Regulatory Activities  
MELD  Model for End -Stage Liver Disease  
mITT  Modified intent to treat  
MMRM  Mixed models repeated measures  
NAFLD  Non-alcoholic fatty liver disease  
NASH  Nonalcoholic s teatohepatitis  
NCI  National Cancer Institute  
NRS  Numerical r ating scale 
OCA  Obeticholic a cid 
PBC  Primary b iliary  cholangitis  
PD Pharmacodynamics  
PK Pharmacokinetics  
PMM  Pattern -mixture model  
PP Per protocol  
PPAR  Peroxisome p roliferator -activated r eceptor  
Pro-C3 N-terminal type III collagen propeptide  
PT Prothrombin time  
QoL Quality of life  
RBC  Erythrocyte count  
SAE  Seriou s adverse event 
SD Standard deviation  
SOC  System organ class  
SUSAR  Suspected unexpected serious adverse r eaction  
TEAE  Treatment -emergent adverse e vent 
UDCA  Ursodeoxycholic acid  
ULN  Upper limit of n ormal  
VAS  Visual analogue scale  
WBC  Leukocyte count  
WHO  World Health Organization  
 
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 9 of 94 2 LIST OF SPONSOR CONTACTS  
Sponsor Contact: 
 
CymaBay Therapeutics, Inc. 
7575 Gateway Blvd, Suite 110 
Newark, CA 94560 
United States of America  
 
 
 
 
The S
ponsor will notify the investigator(s) in writing with any change to the above 
information. 

CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 10 of 94 3 SYNOPSIS  
Study Number  CB8025-31735  
Title  A 52 -week, placebo- controlled, randomized, Phase 3 study to evaluate the 
safety and efficacy of seladelpar in subject s with primary biliary c holangitis 
(PBC) and an inadequate response to or intolerance to ursodeoxycholic acid 
(UDCA)  
Phase  3 
Objectives Primary:  
• To evaluate the safety and effect on cholestasis of two seladelpar 
regimens (5 mg/day titrated to 10 mg/day and 10 mg/day)  over 52 weeks 
of treatment compared to placebo  
Key Secondary:  
• To evaluate the effect of seladelpar on normalization of alkaline 
phosphatase (AP) levels  
• To evaluate the effect of seladelpar on pruritus  
Other Secondary:  
• To evaluate the effect  of seladelpar on quality of life (QoL)  
• To evaluate the effect of seladelpar on other measures of cholestasis, 
metabolic outcomes, and PBC prognosis criteria 
• To evaluate the effect of seladelpar on PBC clinical outcomes 
Exploratory: 
• To evaluate the effect of seladelpar on markers of inflammation, bile ac id 
synthesis, levels of autotaxin, and markers of liver fibrosis  
Study Outcome 
Measures  Primary  Measures : 
• Response on the composite endpoint of AP and total b ilirubin  at 
12 months:  
o AP < 1.67 × upper limit of normal (ULN), and 
o ≥ 15% decrease in AP, and 
o Total b ilirubin ≤ ULN  
• Assessment of treatment -emergent AEs (TEAEs) ( National Cancer 
Institute [ NCI] Common Terminology Criteria for Adverse Events 
[CTCAE ] Version 4.0), biochemistry and hematology  
1. Key Second ary: 
• Proportion of subject s with AP ≤ 1.0 × ULN at 12 months  
• Change from baseline in pruritus numerical rating s cale (NRS) at 
6 months 
Other Secondary:  
• PBC -40 QoL at 6 and 12 months 
• PBC -40 QoL itch domain, and 5-D itch questionnaire 
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 11 of 94 • Response on the compos ite endpoint at 6 months  
• Proportion of subject s with AP <  1.67 × ULN and AP < 1.5 × ULN at 6 
and 12 months 
• Proportion of subject s with AP ≤ 1.0 × ULN at 6 months and 12 months 
• Change from baseline in pruritus NRS at 12 months 
• Absolute and relative changes in AP  
• Proportion of subject s with PBC response criteria (Barcelona, Paris I and 
II, Toronto I and II, Rotterdam )  
• Change in UK -PBC and GLOBE risk scores 
• Absolute and relative changes in alanine aminotransferase (ALT), 
aspartate aminotransferase (AST) , gamm a-glutamyl transferase (GGT), 
bilirubin (total, direct, and indirect), low density l ipoprotein cholesterol 
(LDL -C), high density lipoprotein cholesterol (HDL - C), triglycerides, 
and total c holesterol  
• The first occurrence of any of the following events:  
o Overall Death  
o Liver transplantation 
o MELD score ≥15  
o Uncontrolled ascites (diuretic resistant)  
o Hospitalization for new onset or recurrence of any of the 
following: 
 variceal bleeding  
 hepatic encephalopathy (as defined by a West Haven 
score ≥ 2)  
 spontaneous bact erial peritonitis (confirmed by culture 
from diagnostic paracentesis)  
o Hepatocellular carcinoma 
o Advanced PBC as defined by the Rotterdam criteria (albumin 
below low limit of normal (LLN) AND total bilirubin above 
ULN)  
Exploratory Measures:  
• C4 (7α -hydroxy-4- cholesten -3-one), fibroblast growth f actor 19 
(FGF19) , N-terminal type III collagen propeptide (Pro -C3) 
• Haptoglobin, f ibrinogen and high -sensitivit y C-reactive p rotein (hs -
CRP), homocysteine, i mmunoglobulin M (IgM)  
• Autotaxin  
• Enhanced l iver fibrosis (ELF ) score, f ibrosis-4 (FIB -4) score, Lok-Index, 
non-alcoholic fatty liver disease (NAFLD) fibrosis score  
• Liver e lastography (at selected centers)  
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 12 of 94 Design  Double- blind, randomized, placebo controlled, 52 weeks dose ranging 
(placebo, 5/10 mg/day, and 10 mg/day), parallel treatment groups  
Subjects on 5/10 mg who are tolerating study drug but who are not responding 
to the therapy based on composite endpoint, will have dose adjustment 
performed after 6 months of treatment.  
 
Treatment Groups  • Seladelpar 5/10 mg  
• Seladelpar 10 mg  
• Placebo  
Number of Subjects  Approximately 240 subjects total with  approximately 80 subjects per group   
Number of 
Investigational Sites Approximately 140 worldwide 
Randomization 1:1:1 
Stratification  Randomization will be stratified by t he following factors:  
• AP <  350 U/L and ≥ 350 U/L  
• Pruritus NRS < 4 and NRS ≥ 4  
Duration Screening: up to 2 weeks 
Run-In: 2 weeks 
Treatment: 52 weeks with an option to enter a long -term study (CB8025-
31731) 
Follow-up: 4 weeks (if not enrolled in the long- term study) 
Total Duration: up to 60 weeks  
Test Product, 
Formulation, Dose, 
Frequency, 
Administration 
Route   Seladelpar  Placebo  
Capsules  Identical -looking capsules 
5 and 10 mg NA 
Once a day  Once a day  
Oral Oral 
 
Population PBC subjects  with an inadequate response to UDCA or intolerance to 
UDCA  

CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 13 of 94 Criteria for 
Eligibility  Inclusion Criteria: 
Subjects must meet all  of the following criteria to be eligible for study 
participation: 
1. Must have given written informed consent (signed and dated) and 
any authorizations required by loca l law  
2. 18 to 75 years old (inclusive)  
3. Male or female with a diagnosis of PBC, by at least two of the 
following criteria:  
• History of AP above ULN for at least six months 
• Positive anti -mitochondrial antibody ( AMA) titers (>1/40 on 
immunofluorescence or M2 pos itive by enz yme linked 
immunosorbent assay [ELISA]) or positive PBC- specific 
antinuclear antibodies 
• Documented liver biopsy result consistent with PBC 
4. On a stable and recommended dose of UDCA for the past twelve 
months OR intolerant to UDCA (last dose of UDCA > 3 months prior to 
Screening) 
5. AP ≥ 1.67 × ULN  
6. Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the 
study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use 
barrier contraception and their female partners must use a second 
effective birth control method during the study and for at least 90 days 
after the last dose  
Exclusion Criteria: 
Subjects must not meet any  of the following criteria to be eligible for study 
participation: 
1. Previous exposure to seladelpar (MBX -8025) 
2. A medical condition, other than PBC, that in the investigator’s opinion 
would preclude full participation in the study or confound its results 
(e.g., cancer) 
3. AST above 3 × ULN  
4. ALT above 3 × ULN  
5. Total bilirubin above 2.0 × ULN 
6. Advanced PBC as defined by the Rotterdam criteria (albumin below 
LLN  AND total bilirubin above 1 × ULN)  
7. Creatine kinase (CK) above 1.0 × ULN 
8. eGFR below 60 mL/min/1.73 m2 (calculated by MDRD formula)  
9. International normalized ratio ( INR) above 1.0 × ULN 
10. Platelet count below 100 × 103/µL 
11. Presence of clinically significant hepatic decompensation, including: 
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 14 of 94 - History of liver transplantation, current placement on liver 
transplantation list, or current MELD  score ≥  15 
- Complications of portal hypertension, including known esophageal 
varices, history of variceal bleeds or related interventions ( e.g., 
transjugular intrahepatic portosystemic shunt placement) , relevan t 
ascites, hepatic encephalopathy  
- Cirrhosis with complications, including history or presence of 
spontaneous bacterial peritonitis  
12. Other chronic liver diseases:  
a. Current features of auto -immune hepatitis as determined by the 
investigator based on immunoser ology, liver biochemistry and 
histology 
b. Primary sclerosing cholangitis determined by presence of 
diagnostic cholangiographic findings   
c. History or clinical evidence of alcoholic liver disease  
d. History or clinical evidence of alpha-1- antitrypsin deficiency  
e. Biopsy confirmed nonalcoholic steatohepatitis 
f. History or evidence of Gilbert’ Syndrome  with elevated total 
bilirubin  
g. History or evidence of hemochromatosis  
h. Hepatitis B defined as presence of hepatitis B surface antigen 
(HBsAg)  
i. Hepatitis C defined as presence of HCV RNA  
13. Known history of HIV 
14. Evidence of s ignificant alcohol consumption 
15. Evidence of d rug abuse 
16. Subjects with inadequate response to obeticholic acid ( OCA) or 
intolerance to OCA: OCA must be discontinued 30 days prior to 
Screening 
17. Use of colchicine, m ethotrexate, azathioprine, or long- term systemic 
corticosteroids (> 2 weeks)  within two months prior to Screening 
18. Use of fibrates within 30 days prior to Screening 
19. Use of simvastatin within 7 days prior to Screening  
20. Use of an experimental or unapproved tre atment for PBC within 
30 days  prior to Screening  
21. Use of experimental or unapproved immunosuppressant within 30 days 
prior to Screening  
22. Treatment with any other investigational thera py or device within 
30 days o r within five half -lives, whatever is longer, prior to Screening  
23. For females, pregnancy or breast -feeding 
24. Any other condition(s) that would compromise the safety of the subject 
or compromise the quality of the clinical study, as judged by the 
investigator  
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 15 of 94 Procedures  Screening (Week -4): 
After signing  an informed consent form (ICF), subjects will enter the 
Screening period to confirm eligibility. Demographics will be collected. A 
medical history will be taken, including PBC history, results of prior liver 
biopsy and liver elastography (FibroScan), and alcohol consumption. The 
subject’s medical chart will be reviewed for evidence of other forms of 
chronic liver disease as well as for HIV infection. D etailed treatment history 
will be collected, including previous exposure to UDCA, OCA as well as 
other medications taken for PBC and its symptoms. Vital signs will be 
collected. Height and weight will be collected. Complete physical 
examination will be perf ormed as well as a 12 -lead electrocardiogram 
(ECG). Blood samples will be taken for hematology, biochemis try, AMA , 
Hepatitis B and C. If unexpected elevation of CK or INR is  noted, re -test 
will be allowed. Women of child-bearing potential will have a serum 
pregnancy test performed.  Urine d rug screen will be performed. E- diary 
training will be performed, and s ubject s will complete the pruritus NRS. 
UDCA will be dispensed, and subjects will be instructed to switch their pre-
study UDCA to study suppl y UDCA. Subjects will be instructed to continue 
UDCA regimen (dose and frequency) as close as possible to regimen taken 
prior to the study participation and as recommended per investigator ’s 
clinical judgment.  
Run-In (Week -2): 
Subjects who have been deemed eligible during the Screening  period will 
return for Run -In period.  
AEs since the last visit will be evaluated.  Medication history including 
medications since the last visit will be reviewed. Vital signs and weight will 
be collected. Symptom- directed physical examination will be performed. 
Blood samples will be taken for hematology, biochemistry, and exploratory 
measures. Women of child- bearing potential will have a serum pregnancy 
test performed. Back -up blood sample will be collected. E- diary will be 
dispensed and re -training will be performed, if needed. T he subject will 
complete the pruritus NRS, 5- D itch , PBC -40 QoL, and patient global 
impression of severity (PGI -S) using e-diary. The subject will be instructed 
to use e- diary to evaluate pruritus NRS on a daily basis and 5-D itch on a bi-
weekly basis from the Run -In visit through the first six month of study drug 
treatment . UDCA accountability will be performed. 
Baseline liver biopsy will be performed on subjects willing to undergo  the 
procedure to evaluate PBC stage and activity . PT and INR must be 
performed within 2 weeks prior to liver biopsy. If liver biopsy was 
performed within 1 year from Day 1, B aseline liver biopsy can be waived . 
For these instances sites will attempt to collect biopsy material . A follow up 
liver biopsy will be performed after at least 3 years (± 3 months) of 
treatment during the long -term study (CB8025-31731). 
 
 
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 16 of 94 Day 1:  
Subjects will be randomized into the study.  
AEs since the last visit will be evaluated. Medication history including 
medications since the last visit will be reviewed. Vital signs and weight will 
be collected. A complete ph ysical examination and ECG will be performed. 
Blood samples will be taken for hematology, biochemistry, exploratory 
measures (including fat-soluble vitamins). Back -up blood sample will be 
collected. Women of child-bearing potential will have a serum pregna ncy 
test performed. PBC-40 and PGI -S questionnaires will be performed. A 
review of pruritus NRS  and 5 -D itch  data collected via e- diary since the 
previous visit will be performed. Subjects will be reminded to use e-diary to 
evaluate pruritus NRS on a daily  basis . Liver e lastrography (e.g., FibroScan) 
will be performed at selected sites. Subjects will be dispensed with the study 
drug to be taken orally once a day. Study drug dosing will be initiated 
immediately. UDCA will be dispensed. UDCA accountability wi ll be 
performed.  
If a subject terminates study participation at any point after Day 1, an Early 
Termination visit will be completed.  
Month 1 (Week 4 ± 3 days) : 
AEs since the last visit will be evaluated. Concomitant medication history 
since the last visit  will be reviewed. Vital signs and weight will be collected. 
Brief symptom -directed physical examination will be performed. Blood 
samples will be taken for hematology, biochemistry, exploratory measures. 
Back -up blood sample will be collected. Women of chi ld-bearing potential 
will have a serum pregnancy test. S ubject s will complete PBC -40 QoL, 
PGI-S and patient global impression of change (PGI -C). A review of 
pruritus NRS and 5- D itch data collected via e- diary since the previous visit 
will be performed. Study drug and UDCA accountability will be evaluated. 
Month 3 (Week 12 ± 7 days):   
AEs since the last visit will be evaluated. Concomitant medication history 
since the last visit will be reviewed. Vital signs and weight will be collected. 
Brief symptom -directed physical examination will be performed. Blood 
sample will be taken for hematology, biochemistry, exploratory measures. Back -up blood sample will be collected. Women of child-bearing potential 
will have a serum pregnancy test performed. The subject will complete 
PBC -40 QoL, PGI- S and PGI -C. A review of pruritus NRS and 5- D itch 
data collected via e-diary since the previous visit will be performed. Study 
drug and UDCA accountability will be evaluated. Study drug and UDCA 
will be dispensed.  
Contact 1 (Wee k 19 ± 7 days): 
Subjects will be contacted by phone or email for the following: AEs  will be 
evaluated, concomitant medications and procedures since last visit will be 
reviewed. Compliance with study drug administration will be evaluated. 
Unscheduled visit might be scheduled, if deemed necessary by investigator .  
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 17 of 94 Month 6  (Week 26 ± 7 days):  
AEs will be evaluated. Concomitant Medications will be reviewed. Vital 
signs and weight will be collected. Complete physical examination will be 
performed. A 12- lead ECG will be performed. Blood samples will be taken 
for hematology, biochemistry, exploratory measures. Back -up blood sample 
will be collected. Women of child -bearing potential will have a serum 
pregnancy test performed. The subject will complete 5-D itch, PBC-40 QoL, 
PGI-S and PGI -C. A review of pruritus NRS and 5- D itch data collected via 
e-diary since the previous visit will be performed. Starting from this visit, 
the subject will be instructed to fill out the NRS questionnaire via e- diary 
for 7 consecutive d ays every month through the Month 12 visit; 5- D itch 
will be collected at the clinic visits only. Study drug and UDCA 
accountability will be evaluated. Liver elastography (e.g. FibroScan ) will be 
performed at selected sites.  Study drug and UDCA will be dis pensed.  
Double- blind evaluation for dose up-titration will be performed. Dose up-
titration will be requested if the following criteria are met :  
No safety 
concerns limiting 
up-titration  AND  One of the following criteria:  
o AP ≥ 1.67 × ULN, OR  
o < 15% decrease in AP comparing to 
baseline value, OR  
o Total bilirubin > 1 × ULN  
Dose Adjustment Visit  (2 weeks after Month 6  ± 3 days) 
All subjects will return to the clinic in two weeks after Month 6 visit for 
dose adjustment. For su bjects who have safety concerns limiting up -
titration, Dose Adjustment visit will still occur to evaluate subjects’ status. 
Subjects will be instructed to not to take study drug at home prior to the 
clinic visit. TEAEs will be evaluated. Concomitant medica tions will be 
reviewed. Vital signs and weight will be collected. A brief symptom -
directed physical examination will be performed. A blood sample will be 
taken for hematology, biochemistry, and exploratory biochemistry. A back-
up serum sample will be colle cted. Study drug accountability will be 
evaluated. Additional assessments as determined by the Investigator. Dose 
up-titration will be performed, and the new dose of study drug will be 
administered. 
For subjects who meet the up -titration criteria: subjects  on 5 mg will be 
dispensed seladelpar10 mg; subjects on 10 mg will be dispensed seladelpar 
10 mg, and subjects on placebo will be dispensed matched placebo. Study 
drug will be dispensed in a blinded manner. Subjects will immediately start 
dosing. 
Contact 2 (Week 32 ± 7 days): 
Subjects will be contacted by phone or email for the following: AEs will be 
evaluated, concomitant medications and procedures since last visit will be 
reviewed. Compliance with study drug administration will be evaluated. 
Unscheduled v isit might be scheduled, if deemed necessary by investigator. 
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 18 of 94 Month 9  (Week 39 ± 7 days):  
AEs will be evaluated. Concomitant Medications will be reviewed. Vital 
signs and weight will be collected. Brief symptom -directed physical 
examination will be performed. Blood sample will be taken for hematology, 
biochemistry, exploratory measures. Back -up blood sample will be 
collected.  Women of child- bearing potential will have a serum pregnancy 
test performed. The subject will complete 5 -D itch, PBC-40 QoL, PGI- S 
and PGI -C. A review of pruritus NRS data collected via e- diary since the 
previous visit will be performed. Study drug and UDCA accountability will 
be evaluated. Study drug and UDCA will be dispensed.  
Contact 3 (Week 45 ± 7 days): 
Subjects will be contacted b y phone or email for the following: AEs will be 
evaluated, concomitant medications and procedures since last visit will be 
reviewed. Compliance with study drug administration will be evaluated. 
Unscheduled visit might be scheduled, if deemed necessary by i nvestigator . 
Month 12 (Week 52 ± 7 days):  
AEs will be evaluated. Concomitant Medications will be reviewed. Vital 
signs and weight will be collected. Complete physical examination will be 
performed. A 12-lead ECG will be performed. Blood sample will be taken 
for hematology, biochemistry, exploratory measures (including fat-soluble 
vitamins) . Back -up blood sample will be collected. Women of child-bearing 
potential will have a serum pregnancy test performed. The subject will 
complete 5 -D itch,  PBC-40 QoL, PGI- S and PGI -C. A review of pruritus 
NRS data collected via e-diary since the previous visit will be performed. 
E- diary will be collected. Study drug and UDCA accountability will be 
evaluated. Study supply of UDCA will be switched to pre-study supply 
UDCA. L iver e lastography (e.g. FibroScan)  will be performed at s elected 
sites. At the end of the visit, all subjects will be invited to participate in the 
long-term study (CB8025-31731).  
Subjects who consent to participate in C B8025-31731 will have the 
Month 12 visit combined with the Day 1 visit of  CB8025 -31731. Subjects 
on seladelpar will continue dosing ; subjects on  placebo will initiate 
seladelpar (5 or 10 mg). 
Subjects who do not consent to participate in CB8025-31731 will stop study 
drug and enter the four-week follow-up period.  
Post-Treatment Follow -up: 
Four weeks post -treatment, subjects will return to the clinic for a follow -up 
visit. This will be the subject’s last visit.  
AEs will be evaluated. Concomitant medications will be reviewed. Vital 
signs and w eight will be collected. Complete physical examination will be 
performed, as well as a 12 -lead ECG. Blood sample will be taken for 
hematology, biochemistry, and exploratory measures. Back -up serum 
sample will be collected. Women of child-bearing potential will have a 
serum pregnancy test performed.  
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 19 of 94 Early Termination Visit : 
AEs will be evaluated. Concomitant Medications will be reviewed. Vital 
signs and weight will be collected. Complete physical examination will be 
performed as well as a 12 -lead ECG. Blood sample will be taken for 
hematology, biochemistry, and exploratory measures (including fat-soluble 
vitamins) . Back -up serum sample will be collected. Women of child-bearing 
potential will have a serum pregnancy test performed. The subject will 
complete pr uritus NRS, 5-D itch, PBC -40 QoL, PGI- S and PGI -C. A review 
of pruritus NRS data collected via e- diary since the previous visit will be 
performed. E- diary will be collected. Liver e lastography (e.g. FibroScan) 
will be performed at selected sites. Study drug and UDCA accountability 
will be evaluated. Study supply of UDCA will be switched to pre-study 
supply of UDCA 
Unscheduled Visit : 
AEs will be evaluated. Concomitant Medications will be reviewed. Brief 
symptom-directed physical examination will be performed. Blood samples 
will be taken for biochemistry  and hematology. Additional assessments as 
determined by the investigator . 
UDCA  Subjects with inadequate response to UDCA will continue their UDCA 
intake in approximately the same dose as prior to the study participation and 
as recommended per investigator ’s clinical judgment.  
Concomitant 
Treatment  Subjects will be allowed to receive required medication to treat new or 
existing medical conditions. 
Prohibited 
Treatment  Obeticholic acid  
Fibrates (e.g. fenofibra te, bezafibrate)  
Simvastatin  
Colchicine, methotrexate, azathioprine 
Systemic cortico steroids (>  2 weeks)  
Dose titration Subject will have a dose evaluation performed at the Month 6 visit to 
determine if dose up- titration is necessary. Dose evaluation will  be done in a 
double-blind manner. 
Dose up- titration will occur if the following criteria are met: 
No safety 
concerns 
limiting up -
titration  AND  One of the following criteria:  
o AP ≥ 1.67 × ULN, OR  
o < 15% decrease in AP comparing to 
baseline value, OR  
o Total bilirubin > 1 × ULN  
Subjects who meet the criteria will receive the up -titrated dose at the Dose 
Adjustment visit ( 2 weeks after Month 6 visit ). Subjects on 5 mg will be up-
titrated to 10  mg; subjects on 10  mg will continue 10 mg; and subjects on 
placebo will continue placebo.  
Subjects who do not meet the up- titration criteria will continue the study at 
the initially assigned dose.  
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 20 of 94 Safety Monitoring  
and Drug 
Interruption  Liver Safety Monitoring 
1. Elevation of ALT/AST 
Normal ALT/AST at baseline  
• ALT/AST > 5 × ULN and total b ilirubin ≤ 1 × ULN: Interrupt 
study drug.  Repeat AST, ALT, total bilirubin, and INR within 3 
days and closely follow the subject ( see Appendix B ). Study 
medication can be restarted only if a firm competing etiology is 
identified, and liver tests return to baseline. 
• ALT/AST > 5 × ULN and total b ilirubin > 1 × ULN: 
o Subjects with normal total b ilirubin at baseline: Stop study 
drug.  Repeat AST, ALT, total bilirubin, and INR within 3 
days and closely follow the subject (see Appendix B ). 
o Subjects with elevated total b ilirubin at baseline:  
 Total bilirubin > 1.5 × baseline: Stop study drug.  
Repeat AST, ALT, total bilirubin, and INR within 3 
days and closely follow the subject (see 
Appendix B ). 
 Total bilirubin ≤ 1.5 × baseline: Interrupt study 
drug.  Repeat AST, ALT, total bilirubin, and INR 
within 3 days and closely follow the subject ( see 
Appendix B). Study medication can be restarted only 
if a firm competing etiology is identified, and liver 
tests return to baseline . 
Elevated ALT/AST at baseline:  
• ALT/AST > 3 × baseline AND INR  ≤ 1.5 × ULN AND no liver -
related symptoms (e.g., nausea, vomiting, right upper quadrant pain, 
loss of appetite, dark urine, or jaundice): Continue study drug.  
Repeat AST, ALT , total bilirubin, and INR within 3 days. Closely 
follow the subject (see Appendix B ). 
• ALT/AST > 3 × baseline AND INR  > 1.5 × ULN AND no liver -
related symptoms (e.g., nausea, vomiting, right upper quadrant pain, 
loss of appetite, dark urine, or jaundice): Interrupt study drug.  
Repeat AST, ALT, total bilirubi n, and INR within 3 days and closely 
follow the subject (see Appendix B ). Study drug can be restarted 
only if a firm competing etiolo gy is identified, and liver tests return 
to baseline. 
2. Liver -related symptoms (e.g., nausea, vomiting, right upper quadrant 
pain, loss of appetite, dark urine, or jaundice) AND ALT/AST 
> 3 × baseline (irrespective of baseline levels): Interrupt study drug . 
Repeat AST, ALT, total bilirubin, and INR within 3 days. Closely 
follow the subject (see Appendix B ). Study drug can be restarted only if 
a firm competing etiology is identified, and liver tests return to baseline . 
3. Elevat ion of total bilirubin > 1.5 × baseline, regardless of ALT or AST 
levels, AND indicators of immunological reaction (e.g., rash, 
eosinophilia > 5%) OR liver -related symptoms (e.g., nausea, vomiting, 
right upper quadrant pain, loss of appetite, dark urine, o r jaundice): 
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 21 of 94 Interrupt study drug . Repeat AST, ALT, total bilirubin, and INR 
within 3 days and closely follow the subject (see Appendix B ). Study 
medication can be restarted only if a firm competing etiology is 
identified  and liver tests return to baseline. 
4. Hepatic decompensation (e.g., decompensated cirrhosis  with  gastro -
esophageal variceal bleeding, ascites, or hepatic encephalopathy ) during 
the study : Stop study drug and closely follow the subject (see 
Appendix B ). 
5. Close monitoring of a subject is not possible (see Appendix B ): Stop 
study drug .  
 
Muscle Safety Monitoring  
I. CK > 5 × ULN with musculoskeletal symptoms: S top study drug . 
Repeat the test withi n 3 days. Follow the subject weekly until 
resolution or stabilization.  
II. CK > 5 × ULN without musculoskeletal symptoms: repeat the test 
within 3 days. If on repeat test CK is > 2.5 × ULN, stop study 
drug . Follow the subject weekly until the event resolution  or 
stabilization.  
III. CK > 2.5 × ULN and ≤ 5 × ULN regardless to  musculoskeletal 
symptoms: repeat the test within 3 days. If the test is confirmed, 
study drug will be continued at a decreased dose. For subjects on 
5 mg, the study drug will be switched to placebo. 
Serum Creatini ne Monitoring 
I. Serum Creatinine > 2.0 × ULN: Stop study drug . The subject 
should be monitored weekly until resolution or stabilization.  
II. Serum Creatinine > 1.5 × ULN and ≤ 2.0 × ULN: interrupt study 
drug . Repeat the test within 3 days. If the test is confir med and no 
alternative etiology is identified, stop study drug . If alternative 
etiology is identified, study drug may be restarted after serum 
creatinine returns to baseline values. The subject should be 
monitored weekly until event resolution or stabiliza tion.  
Pancreatic Safety Monitoring  
I. Amylase > 3 × ULN and/or lipase > 3 × ULN without clinical 
symptoms of acute pancreatitis: r epeat the test within 3 days. If the 
test confirms suspicion, interrupt study drug . Abdominal imaging 
is to be performed to excl ude an alternative cause for the event. 
Study drug  might be restarted only if a firm competing etiology of 
acute pancreatitis is identified.  
II. Amylase > 3 × ULN and/or lipase > 3 × ULN with clinical 
symptoms of acute pancreatitis: I nterrupt study drug . Repea t the 
test within 3 days. Abdominal imaging is to be performed to 
exclude an alternative cause for the event . Study drug  might be 
restarted only if a firm competing etiology of acute pancreatitis is identified  
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 22 of 94 Statistics  Study Populations: 
The Safety population includes any subject who receives at least one dose of 
study drug. 
The Intent to Treat (ITT) population includes any subject randomized into 
the study. 
The Modified Intent to Treat (mITT) population includes any subject who is 
randomized into the st udy and receives at least one dose of study drug.  
The Per -Protocol (PP) population includes any subject who receives at least 
one dose of study drug , has at least one post baseline AP and total bilirubin 
evaluation, and does not have a protocol violation that is deemed to impact 
the efficacy analysis.  
Subjects will be analyzed according to randomized treatment assignment.  
Analysis Sets:  
Safety analysis will be conducted on the safety analysis set. Efficacy 
analysis will be conducted on the mITT analysis se t and the PP analysis set . 
The mITT analysis set will be used for the primary efficacy analysis.  
Baseline is defined as the arithmetic mean of multiple pre -treatment 
measurements (Screening, Run-In, Day 1, and UNS if applicable) preceding 
the first admini stration of study drug, or as the last measurement prior to the 
first administration of study drug if only single value is available.  
Descriptive statistics such as means, medians, minimum, maximum and 
measures of dispersion will be presented.  
Primary anal ysis: 
The primary efficacy analysis will be based on the following composite 
endpoint evaluated after 52 weeks of treatment: 
• AP < 1.67x ULN, 
• AP decrease of ≥ 15%, and  
• Total bilirubin ≤ ULN 
Treatment comparisons of the primary efficacy endpoint will be tested using a gateway method. A hierarchical “fixed -sequence” approach will be used to 
evaluate the primary endpoint as follows:  
1. The composite endpoint and seladelpar 10 mg vs placebo if negative stop 
2. If positive,  then:  
3. The composite endpoint and for seladelpar 5/10 mg vs placebo, if 
negative stop  
This testing procedure maintains the overall Type I error for the primary 
efficacy endpoint at 5%. A dditional details including a schematic for the 
testing sequence can be found in the statistical analysis section of the 
protocol.  
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 23 of 94 All inferential tests will be performed at the 5% alpha level.  
Response rates will be calculated based on the observed case analysis (i.e., 
[n=observed responder]/[N=modified Intention to Treat (mITT) 
population]) 
The primary efficacy analysis will be conducted on the mITT analysis set 
using the Cochran- Mantel -Haenszel (CMH) General Association test. The 
CMH analysis will be s tratified by baseline AP randomization (AP level 
< 350 U/L and ≥ 350 U/L)  and pruritis NRS < 4 and NRS  ≥ 4.  
In the primary analysis, subjects who discontinue treatment will be 
considered non- responders. Sensitivity analyses will be performed on the 
primary efficacy endpoint using observed data only. The r obustness of the 
primary analysis will be explored using several sensitivity analyses based on 
different subject  populations including treating subjects who discontinue 
study treatment:  
• As responders 
• Same as primary analysis except based on the ITT Set.  
• Same as primary analysis except based on the PP Set.  
• Same as primary analysis except impute dropouts as non -responders 
in the seladelpar arm and as responders in the placebo arm (i.e. 
worst -case analysis).  
• Same as primary analysis except impute missing data using a 
pattern -mixture model (PMM) which considers different 
mechanisms for missing data.  
• Same as primary analysis except specify the proportion of patients 
achieving a decrease in AP as at least 10%, 20%, and 40%.  
• Using Medians instead of arithmetic means for baseline values  
Key Secondary Analyses:  
• normalization of AP at 12 months (i.e. AP ≤ ULN), and 
• change from baseline in the weekly averaged peak pruritus NRS  
over 6 months 
Type I error for key secondary efficacy analysis will be maintained using the hierarchical fixed -sequence . The fixed sequence approach for the 
primary and secondary analyses is as follows:  
• If the primary efficacy analysis is positiv e for 10 mg vs placebo and 
5/10 mg vs placebo, then the two key secondary endpoints will be 
analysed  hierarchically in the following order: 
1. Normalizat ion of AP at month 12: seladelpar 10 mg vs placebo, if 
negative stop, if positive then;  
2. Normalization of AP at month 12: seladelpar 5/10 mg vs placebo if 
negative stop, if positive then;  
3. Absolute change from baseline to month 6 in pruritus NRS: 
seladelpar 10 mg vs placebo  if negative stop, if positive then;  
CymaBay Therapeu tics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 24 of 94 4. Absolute change from baseline to month 6 in pruritus NRS: 
seladelpar 5/10 mg vs placebo , stop 
Normalization of AP is a responder analysis and will be conducted in the 
mITT set using the same approach spe cified for the primary efficacy 
analysis.  
Additional analyses of pruritus, including durability of response to 
Month 12, will be described in SAP. 
Other Analys es: 
• The first occurrence any of the following events:  
o Overall Death  
o Liver transplantation 
o MELD sc ore ≥  15 
o Uncontrolled ascites (diuretic resistant)  
o Hospitalization for new onset or recurrence of any of the 
following: 
 variceal bleeding  
 hepatic encephalopathy (as defined by a West 
Haven score ≥ 2)  
 spontaneous bacterial peritonitis (confirmed by 
culture from diagnostic paracentesis)  
o Hepatocellular carcinoma 
o Advanced PBC as defined by the Rotterdam criteria (low 
serum albumin AND total bilirubin above 1 × ULN)  
Clinical events will be validated by a Critical Event Review Committee 
(CERC) composed of independent clinical experts familiar with hepatic diseases.  
Sample size:  
The planned sample size is 240 subjects (80 subjects in each of the 
3 groups). The placebo group responder rate is estimated at less than 15%. 
The seladelpar 10 mg dose group responder ra te is estimated at 40%. With 
the use of a 2 -sided test of equality of binomial proportions based on 
Pearson chi -square test at the 5% level of significance, a sample size of 
80 subjects per group will provide greater  than 90% power to detect a 
difference b etween the 10 mg seladelpar group and the placebo group. 
Normalization of AP  is estimated to have a placebo response rate of 5%. 
A 2-sided test of equality of binomial proportions based on Pearson chi-
square test at the 5% level of significance yields a sample size of 80 subjects  
per group. This sample size provides more than 90% power to detect a difference of 30% between the seladelpar and placebo groups. 
Change in pruritus NRS sample size calculation w as based on a 2 -sample 
2-sided t- test at the 5% alpha  level. The standard deviation is 3. Under these 
assumptions, a total of 23 subjects per group provides ≥90% power to detect 
a treatment difference of ≥  3 between the 10 mg seladelpar and placebo 
groups.  
 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 0.1, 30- APR -2018  CONFIDENT IAL Page 25 of 94 Table 1 Schedule of Assessments  
Visit  Screening  Run-In Randomi -
zation  Month 
1 Month 
3 Contact 
11 Month 
6 Dose 
Adjust  Contact 
21 Month 
9 Contact 
31 Month 
1212 Follow 
Up ET UNS  
Target Day  W-4 to -2 W -2 Day 1  W 4 W 12 W 19  W 26 W28  W 32  W 39  W 45  W 52 4W after  
W52    
Informed Consent  X               
Demographics                 
Eligibility  X               
Randomization    X             
Dose Evaluation2       X         
Up-Titration         X        
Medical History3 X               
AE  X X X X X X X X X X X X X X 
Prior and Concomitant 
Medi cations  X X X X X X X X X X X X X X X 
Vital Signs and Weight  X X X X X  X X  X  X X X  
Height  X               
Physical Exam  X X4 X X4 X4  X X4  X4  X X X X4 
ECG  X  X    X     X X X  
Hematology5, 6 X X X X X  X X  X  X X X X 
Biochemistry5 X7 X X X X  X X  X  X X X X 
Exploratory Measures5 X8 X X8 X X  X X  X  X8 X X8  
Hepatitis B and C  X               
Serum Pregnancy Test9 X X X X X  X   X  X X X  
Back -up Blood Sample5  X X X X  X   X  X X X  
Urine Drug Screen  X               
Pruritus NRS10 X X X X X  X   X  X  X  
5-D itch10  X X X X  X   X  X  X  
PBC -40 QoL10  X X X X  X   X  X  X  
PGI-S10  X X X X  X   X  X  X  
PGI-C10    X X  X   X  X  X  
Liver Elastography 
(selected sites)    X    X     X  X  
Liver Biopsy11  X              
UDCA Dispense  X  X  X  X   X      
Study Drug Dispense    X  X  X X  X      
Study Drug 
Compliance and 
Accountability     X X X13 X X X13 X X13 X  X  
UDCA Accountability   X X X X  X   X  X  X  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 0.1, 30- APR -2018  CONFIDENT IAL Page 26 of 94 Abbreviations:  AE=adverse event; AMA=anti -mitrochondrial antibodies; ECG=electrocardiogram; ET=Early Termination; NRS=numerical rating scale; PBC=primary biliary cholangitis; PGI -
C=patient global impression of change; PGI -S; patient global impression of severity; QoL=quality of life; UDCA=ursodeoxycholic acid; UNS=Unscheduled visit ; W=week .  
1. Subject contact will be performed by  phone or email communication. 
2. All subjects will be evaluated for dose up -titration in a blinded manner. For subjects who met the up- titration criteria, dose up -titration will be requested. Dose up-titration will occur at Dose 
Adjustment visit. 
3. Including PBC histor y, liver biopsy, liver elastography , alcohol consumption, evidence of other form of liver disease, and HIV .  
4. Symptoms -directed (brief) physical examination . 
5. Blood will be collected after at least an 8-hour overnight fast. If the subject forgets to fast prior to the blood collection, the site will record it in the source document and continue to draw 
labs.  
6. PT and INR will also be performed locally at the Screening visit, Run -In, and during the treatme nt period if deemed necessary by the Investigator.  
7. If at Screening an unexpected abnormal CK level is observed, re-test the subject to confirm eligibility . 
8. Screening visit : only AMA will be performed. Fat -soluble vitamins will be performed at Day 1 , Week 5 2 and ET (if applicable)  only.  
9. Serum pregnancy test will be performed in women of childbearing potential only.  Additional on- treatment pregnancy testing may be performed at the investigator’s discretion or per local 
regulatory requirements.  
10. Pruritus NRS, 5-D itch, PBC -40, and PGI -S and PGI -C data will be collected via e-diary. Subjects will be asked to complete (1) pruritus NRS: on a daily basis from the Run-In Visit and 
through the first 6 months of treatment. After six months  NRS will be collected for se ven consecutive days during each month up to the Month 12 visit. (2) 5-D itch  will be collected bi-
weekly from the Run -In Visit  up until  the Month 6 visit; after Month 6 5 -D itch will be collected at clinic visit only. 3)  PBC- 40, PGI-S, PGI-C will be collected during the clinic visits  only.  
11. Only s ubjects willing to undergo liver biopsy. PT and INR must be performed within 2 weeks prior to liver biopsy. If a subject had liver biopsy performed within 1 year from Day 1, sites 
will attempt to collect biopsy m aterial. A follow up liver biopsy will be performed after 3 years (± 3 months) of treatment during long -term study (CB8025 -31731).   
12. Subjects will be invited to participate in the long -term study (CB8025 -31731). Subjects who consent to participate in CB8025-31731 will have the Month 12 visit com bined with the Day  1 
visit in the CB8025 -31731 study and continue dosing.  
13. Only study drug compliance to be evaluated 
 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL Page 27 of 94 4 INTRODUCTION 
4.1 Primary Biliary Cholangitis (PBC)  
Primary biliary c holangitis (PBC, formerly known as primary biliary c irrhosis) is a serious 
and potentially life threatening autoimmune disease of the liver characterized by impaired 
bile flow (cholestasis) and accumulation of toxic bile acids (BA).  
The hallmark of PBC is cholestasis with an accompanying elevation in serum biomarkers including alkaline phosphatase (AP), gamma glutamyl transferase (GGT) and, depending on the severity of the disease, bilirubin and liver transaminases. Serologically, PBC is characterized by the presence of anti -mitochondrial a ntibodies (AMA) in nearly all patients 
(Selmi, 2010). Clinical symptoms of PBC include pruritus and fatigue, which can be quite 
disabling for some patients. PBC peak incidence occurs in the fifth decade of life and is uncommon in persons under 25 years of age ( Kaplan , 2005). The histopathology in the livers 
of PBC patients is characterized by portal inflammation and immune -mediated destruction of 
intrahepatic bile ducts. These chan ges occur at different rates and with varying degrees of 
severity. The loss of bile ducts leads to decreased bile secretion and the retention hydrophobic BA within the liver, resulting in hepatocellular injury, fibrosis, cirrhosis and eventually liver failure ( Kaplan , 2005; Kumagi , 2008; Lindor , 2007). PBC is a chronic 
debilitating disease whose progression is associated with an increased ris k of hepatocellular 
carcinoma and liver related mortality ( Kaplan , 2005; Kumagi , 2008; Lindor , 2007).  
The diagnosis of PBC often occurs at an early stage when following up on abnormal liver tests, especially elevated AP. After excluding extra-hepatic biliary obstruction, the presence of either AMA, or less often, the histological confirmation by liver biopsy establish es the 
diagnosis ( Lindor , 2009 ). Fifty to 60% of patients are asymptomatic at diagnosis. Overt 
symptoms develop within two to four years in most asymptomatic patients, although one-third may remain symptom- free for years ( Kaplan , 2005). Fatigue and pruritus are the most 
common presenting symptoms ( Kaplan , 2005). Fatigue has been noted in up to 78% of 
patients and can be a significant cause of disability. The severit y of fatigue is independent of 
the severity of the liver disease and there is no proven treatment ( Kaplan , 2005). Pruritus, 
whose cause is uncertain, occurs in 20 to 70% of patients and can be extremely debilitating (Rishe , 2008). Other findings of PBC include jaundice, hypercholesterolemia, osteopenia and 
osteoporosis and coexisting autoimmune diseases (Kaplan , 2005; Kumagi , 2008). Portal 
hypertension is a late complication of the disease  (Kaplan , 2005).  
The first line therapy for PBC is ursodeoxycholic acid  (UDCA ), a non- cytotoxic BA that has 
been the mainstay of tr eatment for more than twenty years ( Poupon, 1997). However, up to 
40 percent of patients have persistent elevation of AP and/or bilirubin despite UDCA and are considered inadequate responders ( Corpechot , 2008).  
Obeticholic acid (OCA), a synthetic analogue of chenodeoxycholic acid (CDCA), was approved under the provisions of accelerated approval regulations (21 Code of Federal Regulations [ CFR ] 314.500) in the United States and European Union on 27 May 2016 and 
12 December 2016, respectively. The approval was based on OCA’s ability to significantly decrease AP  levels and maintain a normal total bilirubin  when, used as an add-on therapy in 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 28 of 94 PBC patients who are inadequate responders to UDCA or, as a monotherapy in PBC patients 
who are intolerant to UDCA ( Ocaliva, 2016 ). 
In summary, despite the previously mentioned therapeutic interventions and recent approval of OCA, it is evident that many PB C patients do not respond adequately to therapy and 
continues to have a progression of their disease (Kaplan , 2005; Kumagi , 2008; 
Momah , 2014) and additional treatments are needed. 
4.2 Seladelpar  
4.2.1 Overview  
Seladelpar (MBX -8025) is an oral, once-daily administered, potent and selective peroxisome 
proliferator -activated receptors (PPAR)  δ agonist ( Bays , 2011; Jones , 2017). Seladelpar  is 
being developed for the treatment of PBC in subjects with inadequate response t o UDCA or 
intole rance to UDCA and in nona lcoholic steatohepatitis (NASH) . 
4.2.2 Mechanism of Action  
PPARδ agonists have been shown to affect the transport, storage and metabolism of lipids (Barish , 2006). Seladelpar improves cholestasis no tably by decreasing the synthesis of bile 
acids in hepatocytes thus preventing their toxic accumulation. The decreased synthesis results in part from the down regulation of the gene for CYP7A1, the key enzyme for the synthesis of bile acids.  Seladelpar als o decreases the synthesis of cholesterol as well as inhibiting its 
dietary absorption; these effects decrease the amount of cholesterol available as substrate for bile acid synthesis, thereby enhancing its effect on CYP7A1 in reducing total bile acid  pools. 
Each of the above actions of seladelpar have been demonstrated in PBC patients (Jones , 2017). In addition, seladelpar exerts anti -inflammatory effects ( Jones , 2017) that are 
of potential benefit in the treatment of PBC.  
For more detailed information, see the I nvestigator ’s Brochure (IB). 
4.3 Nonclinical Investigations with Seladelpar  
Please see the IB for details on the nonclinical studies conducted with seladelpar . 
4.4 Human Experience  
Across the clinical development program, seladelpar was evalu ated in 6 Phase 1 studies and 
4 Phase 2 studies. Seladelpar tested doses have ranged from single dose studies in healthy volunteers (1, 5, 15, 60, 120, and 360 mg), to daily long- term dosing in Phase 2 studies in 
patients with mixed dyslipidemia (50 and 100 mg once a day), homozygous familial hypercholesterolemia (HoFH; ascending doses 50, 100, and 200 mg once a day), and PBC (2, 5, 10, 50, and 200 mg once a day). In these Phase 2 studies, treatmen t ranged from 8 to 12 
weeks. In the ongoing Phase 2 PBC study, seladelpar is now being tested for 52 weeks at the 
end of which subjects are entering long- term extension  study and continue dosing beyond 52 
weeks.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 29 of 94 4.4.1 Phase 1 S tudies  
Six Phase 1 clinical studi es have been conducted in healthy subjects. The aims of these 
studies were to evaluate the safety, tolerability, pharmacokinetics ( PK), and 
pharmacodynamics (PD) of seladelpar . A total of 1 47 healthy subjects have been dosed with 
either seladelpar , seladelpar  in combination with other agents, or placebo in the 6 completed 
clinical studies. Seladelpar was administered as a solution in sterile water , or as a hard gelatin 
capsule.  In the 6 Phase 1 clinical studies , seladelpar  was generally well tolerated . There were 
no deaths or serious adverse events ( SAEs ) recorded. All adverse events ( AEs) were mild or 
moderate in severity. The type and incidence of AEs were generally similar across the 
various seladelpar and placebo dose groups. Please see the IB for more complete details on the Phase 1 studies conducted with seladelpar . 
4.4.2 Phase 2 S tudies in PBC Patients  
As of 2018, CymaBay conducted 3 clinical studies with seladelpar in PBC subjects.  
Study CB8025- 21528 was the first clinical study of the seladelpar for the treatment of PBC 
(Jones , 2017). It was a double-blind, randomized, placebo-controlled, 12-week dose- ranging 
study (referred to as the “high dose” study) in adult PBC patients who had an inadequate response to UDCA. Subj ects were randomly assigned to receive 50  mg/day seladelpar, 
200 mg/day seladelpar, or placebo in a 1:1:1 ratio. The study was terminated approximately mid-way through enrollment (41 subjects had enrolled) after 3 patients experienced, rapi d, 
asymptomatic and reversible Grade 3 elevations in alanine aminotransferase (ALT) (one case at 50 mg and two cases at 200 mg). Although CymaBay elected to terminate the study early when a transaminase elevation signal was observed, all subjects receiving seladelpar, including subjects with transaminase elevation, exhibited a pronounced decrease in AP that was evident after the first 2 weeks and was sustained for the duration of the study ( Figure  1; 
Panel A). Subjects who received  seladelpar beyond 2 weeks showed a consistent and 
continual decrease in AP. All subjects who received seladelpar for 12 weeks normalized their AP levels  (Jones , 2017).  This study also provided important information supporting the 
mechanism of action of seladelpar for the treatment of PBC. Treatment with seladelpar was associated with a decrease in C4, which represents a serum marker for the rate of hepatic BA  
synthesis. C4 reflects the activity of CYP7A1, the rate limiting enzyme for the synthesis of BA.  
A second Phase 2 study (CB8025-21629) is currently underway in PBC patients who either have had an inadequate response to UDCA or are intolerant to UDCA. The aim of this study is to further evaluate the safety and efficacy of seladelpar at lower doses.  The interim 
analysis was performed to evaluate the data up to 12 weeks evaluated seladelpar doses of 2, 5 and 10 mg/day. Data up to 26 weeks evaluated doses of 5 and 10 mg/day. After 12 weeks, patients on 5 mg could escal ate to 10 mg if their AP treatment goal was not achieved.  As of 
January 2018, 71 patients were exposed to at least one dose of seladelpar, of whom 53 received 12 weeks of treatment and 42 received 26 weeks of treatment. The 5 and 10 mg doses show consistent, meaningful, and reproducible decreases in AP levels ( Figure  1; Panel 
B). At baseline, mean AP was  358, 333, and 262 IU/L in the 2, 5, and 10 mg groups, 
respectively. At 12 w eeks, changes in AP were -21%, -33%, and -45% in the 2 (N=6), 5 
(N=25), and 10 (N=22) mg groups, respectively. At 26 weeks, 69%, 67%, and 79% of 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 31 of 94 Seladelpar did not increase pruritus. Baseline median pruritus visual analogue scale ( VAS ) 
was 10 and 40 in the 5 and 10 mg  group, respectively, and patients in the 10 mg group 
experienced consistent decreases during follow up ( -24% at week 26). Seladelpar was 
generally safe and well tolerated, with no transaminase elevation safety signal. There were 6 
serious AEs and none wer e deemed related to seladelpar. As a result of interim analys is, it 
was concluded that seladelpar doses of 10 mg, or 5 mg adjusted to 10 mg, demonstrates potent anti- cholestatic efficacy that is maintained over 26  weeks.  
A third study (CB8025-31731) is also underway in PBC patients who completed CB8025-21629 study and willing to continue the treatment with seladelpar beyond 52 weeks. 
4.4.3 Phase 2 S tudies  in N on-PBC P atients  
Study M8025-20711 was a multicenter randomized, double-blind, placebo-controlled study 
to evaluate the safety, tolerability, PK and efficacy of seladelpar  at doses 10 and 100 mg in 
moderately obese hyperlipidemic subjects  with or without concomitant atorvastatin  
(Bays , 2011; Choi , 2012).  
Study CB8025-21427 was a pilot study of seladelpar in the treatment of HoFH. The study was a 12 -week, open label, multicenter, non -controlled, monthly dose escalation study 
(seladelpar : 50, 100, and 200 mg; p.o. daily) in adults with ge netically confirmed HoFH.  
For more details about th e studies, please refer to the IB.  
4.5 Risk/Benefit Assessment  
The study being proposed is a placebo -controlled, double-blind randomized study to evaluate 
safety and efficacy of seladelpar  in PBC subjects. 
4.5.1 Potential Benefits  
In previous PBC studies, subjects receiving placebo showed no relevant change, while subjects receiving seladelpar exhibited a pronounced decrease in AP. After 26 weeks of 
treatment with seladelpar 10 mg and 5 /10 mg, 78% and 68% reached A P <1.67 
× ULN, and 
32% and 26% of subjects had a normal AP, respectively. Additional biochemical markers of cholestasis such as GGT and 5’ nucleotidase were also reduced by seladelpar. Seladelpar also produced potentially beneficial metabolic and anti- inflammatory effects.  
Previous studies in PBC subjects also suggested the potential of seladelpar to improve pruritus, an important clinical outcome in PBC patients.  A decrease in the p ruritus VAS was 
noted in the 10 mg group in which approximately half of pat ients had a substantial level of 
itching at baseline (VAS  ≥ 40 mm, or moderate to severe itch). This suggests that seladelpar 
treatment could be associated with an improvement in PBC- associated itch.  
Subject s who will successfully complete this study can be rolled over into the long- term 
study (CB8025-31731) and can continue their seladelpar treatment  until seladelpar is 
commercially available or the program is discontinued ; subjects on placebo will be switched 
to the active treatment with s eladelpar .  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 32 of 94 4.5.2 Potential Risks  
4.5.2.1 Non-clinical  Safety Findings  
Please see the I B for more complete details on the nonclinical studies conducted with 
seladelpar . 
4.5.2.2 Human S afety  
Currently , seladelpar has been used for a maximum of 21 days in healthy volunteers at a 
maximum dose of 200 mg per day; in overweight subjects with mixed dyslipidemia, with and 
without atorvastatin, for a maximum of eight weeks and with a maximum dose of 100 mg per day; in subjects with HoFH, on concomitant ezetimibe and maximum statin therapy ( ± low 
density lipoprotein cholesterol [ LDL -C] apheresis), with dose escalation from 50 mg to a 
maximum of 200 mg per day; and in subjects with PBC on concomitant UDCA for 12 weeks with a maximum dose of 200 mg per day and for 52 weeks and beyond with a maximum dose of 10 mg per day. 
Seladelpar  has been associated with increases in transaminases (ALT  and aspartate 
aminotransferase [AST] ), particularly in subjects with PBC  treated with seladel par at doses 
50 mg  and 200 mg . The increases appear  to be dose dependent and population dependent. 
The increases were fully reversible up on treatment discontinuation. No clear transaminase 
elevation signal was seen in PBC subject treated with seladelpar at doses 5 and 10 mg. Seladelpar  has been associated with a pre- clinical muscle toxicity signal. One PBC subject 
taking 200 mg per day discontinued seladelpar for acute muscle pain associated with 
increased muscle enzymes. The AE  was reversible upon treatment discontinuation and was 
considered possibly related to treatment. Muscle toxicity signal was not seen in PBC subject treated with selad elpar at doses 5 and 10 mg. 
Seladelpar has been associated with increases in serum creatinine. These increases are generally mild (in the 10% range) and serum creatinine shifts are within the normal range. Similar increases have been observed with drugs of the PPARα class or the mixed PPARα/δ class. In the short term, these increases in serum creatinine have not been associated with relevant decreases in measured glomerular filtration rate. In the long run, data from controlled clinical trials do not suppor t that PPARα or mixed PPARα/δ are associated with a 
degradation of renal function. It is hypothesized that the increase in serum creatinine is of muscle origin (with an increase in creatine synthesis , which is later metabolized into 
creatinine). However, c aution must be exercised. One subject with HoFH and a chronic renal 
insufficiency, treated with seladelpar  100 mg and one subject with PBC treated with 
seladelpar  200 mg had serum creatinine elevation above the normal range that were 
reversible upon treatment discontinuation and considered possibly related to seladelpar . No 
subjects treated with low doses of seladelpar (up to 10 mg) experienced Grade 2 or Grade 3 increases in serum creatinine. Therefore, it was concluded that the seladelpar at doses up to 10 mg had no clinically relevant impact on serum creatinine levels.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 33 of 94 4.6 Rationale for Dose Selection 
In PBC  studies seladelpar at dose of 2, 5, and 10 mg, retains a relevant clinical activity to 
improve markers of cholestasis  and inflammation  as well as  metabolic markers (e.g., 
decrease in triglycerides  and LDL -C). There was a dose ranging activity from 2 to 10 mg/day 
with 10 mg/day demonstrating the best risk/benefit profile. For these reasons, a seladelpar a 
dose of 10 mg/day and dose titration regimen of 5 mg  with a potential to increase to 10 mg 
have been selected for the proposed Phase 3  study.  These doses were well tolerated, appeared 
safe and were not associated with drug-induced pruritus. 
4.7 Conclusions  
In conclusion, seladelpar demonstrated the potent and r apid decrease in biochemical markers 
of cholestasis (AP, GGT, and total bilirubin), decrease a marker of inflammation (hs- CRP) 
and decrease LDL -C in PBC subjects who had an inadequate response or intolerance to 
UDCA. In addition, the current data suggest t hat seladelpar  has a potential to improve 
PBC -related pruritus. L ower doses of seladelpar (up to 10 mg) were generally safe and well 
tolerated. There was no evidence that seladelpar was associated with transaminase elevation s 
at these doses. There was also  no evidence that seladelpar induced or worsened pruritus. T he 
clinical experience with seladelpar is nonetheless limited, and appropriate precautions are 
incorporated into this protocol, with careful monitoring of potential transaminase elevations. 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 34 of 94 5 STUDY OBJECTIVES  
5.1 Primary Objectives  
The primary objective of this study is to evaluate the safety and effect on cholestasis of 
2 seladelpar dose regimens (5 mg/day titrated to 10 mg/day and 10 mg/day) over 52 weeks of 
treatment compared  to placebo . 
5.2 Secondary Obj ectives  
The key secondary objectives of this study are to evaluate the effect of seladelpar on 
normalization of AP  levels and to evaluate the effect of seladelpar on pruritus . 
Other secondary objectives of the study are to evaluate the effect of seladelpar  on quality of 
life (QoL) , to evaluate the effect of seladelpar on other measures of cholestasis, metabolic 
outcomes, PBC prognosis criteria , and the effect on PBC clinical outcomes.  
5.3 Exploratory Objectives 
The exploratory objectives of the study are to evaluate the effect of seladelpar on markers of inflammation, bile acid synthesis , levels of autotaxin , and markers of liver fibrosis. 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 35 of 94 6 STUDY POPULATION 
PBC s ubjects  with an inadequate response to UDCA or intolerance to UDCA.  
6.1 Selection Criteria   
6.1.1 Inclusion Cr iteria  
Subjects must meet all  of the following criteria to be eligible for study participation: 
1. Must have given written informed consent (signed and dated) and any authorizations 
required by local law  
2. 18 to 75 years old (inclusive) 
3. Male or female with a di agnosis of PBC, by at least 2 of the following criteria: 
• History of AP above ULN for at least 6 months 
• Positive AMA titers (>1/40 on immunofluorescence or M2 positive by enzyme 
linked immunosorbent assay [ELISA]) or positive PBC- specific antinuclear 
antibodies  
• Documented liver biopsy result consistent with PBC 
4. On a stable and recommended dose of UDCA for the past twelve  months OR intolerant 
to UDCA (last dose of UDCA > 3 months prior to Screening ) 
5. AP ≥ 1.67 × ULN  
6. Females of reproductive potential must use a t least one barrier contraceptive and a 
second effective birth control method during the study and for at least 90 days after the 
last dose. Male subjects who are sexually active with female partners of reproductive 
potential must use barrier contraception and their female partners must use a second 
effective birth control method during the study and for at least 90 days after the last 
dose  
 
6.1.2 Exclusion Criteria  
Subjects must not meet any  of the following criteria to be eligible for study participation: 
1. Previous exposure to seladelpar (MBX-8025) 
2. A medical condition, other than PBC, that in the investigator’s opinion would 
preclude full participation in the study or confound its results (e.g., cancer) 
3. AST above 3 × ULN 
4. ALT above 3 × ULN 
5. Total bilirubin above 2.0 × ULN 
6. Advanced  PBC as defined by the Rotterdam criteria (albumin below LLN AND total 
bilirubin above 1 × ULN)  
7. Creatine kinase (CK) above 1.0 × ULN  
8. eGFR below 60 mL/min/1.73 m2 (calculated by MDRD formula)  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 36 of 94 9. International normalized ratio (INR) above 1.0 × ULN  
10. Platelet count below 100 ×  103/µL 
11. Presence of clinically significant hepatic decompensation, including: 
- History of liver transplantation, current placement on liver transplantation list, or 
current MELD  score ≥ 15 
- Complications of portal hypertension, including known esophageal varices, 
history of variceal bleeds or related interventions ( e.g., transjugular intrahepatic 
portosystemic shunt placement) , relevant ascites, hepatic encephalopathy  
- Cirrhosis with complications, including history or presence of spontaneous 
bacterial peritonitis  
12. Other chronic liver diseases:  
a. Current features of auto -immune hepatitis as determined by the investigator 
based on immunoserology, liver biochemistry and histology 
b. Primary sclerosing cholangitis determined by presence of diagnostic 
cholangiographic findings   
c. History or clinical evidence of alcoholic liver disease  
d. History or clinical evidence of alpha-1- antitrypsin deficiency  
e. Biopsy confirmed nonalcoholic steatohepatitis  
f. History or evidence of Gilbert’ Syndrome with elevated total bilirubin  
g. History or evidence of hemochromatosis 
h. Hepatitis B defined as presence of hepatitis B surface antigen (H bsAg)  
a. Hepatitis C defined as presence of HCV RNA  
13. Known history of HIV  
14. Evidence of significant alcohol consumption 
15. Evidence of drug abuse  
16. Subjects with inadequate response to OCA or intolerance to OCA: obeticholic acid 
must be discontinued 30 days prior to Screening 
17. Use of colchicine, methotrexate, azathioprine, or long- term systemic cortico steroids 
(> 2 weeks) within two months prior to Screening  
18. Use of fibrates within 30 days prior to Screening 
19. Use of simvastatin within 7 days prior to Screening 
20. Use of an experimental or unapproved treatment for PBC within 30 days prior to 
Screening  
21. Use of experimental or unapproved immunosuppressant within 30 days prior to 
Screening  
22. Treatment with any other investigational therapy or device within 30  days or within 
five half -lives, whatever is longer, prior to Screening 
23. For females, pregnancy or breast -feeding  
24. Any other condition(s) that would compromise the safety of the subject or 
compromise the quality of the clinical study, as judged by the investigator  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 37 of 94 7 STUDY DESIGN  
This Phase 3 study will utilize an international, multicenter, double -blind, randomized, 
placebo -controlled 52-week dose- ranging (p lacebo, 5/10 mg/day, and 10 mg/day), parallel 
treatment groups design .  
This study is a pivotal study to evaluate the safety of seladelpar and its  effect (± UDCA) on 
cholestasis and on pruritus in subjects with inadequate response to UDCA or intolerance to 
UDCA. The study population can also include subjects with an inadequate response to UDCA + OCA, or who are intolerant to OCA.  
The study is planned to enroll approximately 240 subjects . Subjects will be randomly 
assigned to receive placebo, seladelpar 5  mg titrated to 10  mg, or seladelpar 10 mg. Subjects 
will be stratified by AP level ( AP < 350 U/L and ≥ 350 U/L ) and presence of signi ficant 
pruritus (pruritus numerical rating scale [NRS] <  4 and NRS ≥ 4). Subjects will be 
considered as formally entered the study at the time of randomization.  
Study drug (placebo or seladelpar) will be taken in a blinded manner orally once a day for a period of 52 weeks. After first 6 months of treatment, evaluation of the initially assigned dose will be performed in a blinded manner. Subjects assigned to the seladelpar 5/10 mg group who are not responders based on composite endpoint at Month 6, and are tolerating 
study drug, will be up titrated from seladelpar 5 to 10 mg for the remainder  of the study. 
Those patients initially  assigned to placebo or 10 mg will not have their dose changed. To 
avoid unblinding, all subjects will be invited to Dose Adjustment visit which will occur two weeks after Month 6 visit.  
Subjects with an inadequate response to UDCA will continue to receive UDCA  throughout 
the study. Study specific UDCA  supply will be provided and taken during the study 
participation. UDCA supply will be switched from pre- study supply to the study supply at 
the Screening visit and continue through the Week 52 visit. At the Week 52 visit, UDCA will 
be switched to pre- study supply.  
Subjects will be asked to use an e-diary to evaluate pruritus and quality of life during the study participation. E -diary will be dispensed at the Run- In visit and will include the 
following questionnaires: pruritus NRS, 5-D itch, patient global impression of severity (PGI-S), patient global impression of change (PGI- C), and PBC-40. Subjects will perform 
evaluation of their pruritus in a daily basis via pruritus NRS starting from  the Run- In visit 
through the first 6 months of treatment. After  six months, pruritus will be evaluated in a 
monthly basis using pruritus NRS for 7 consecutive days  each month. 5- D itch  will be 
evaluated bi -weekly from the Run -In visit up until the Month 6 visit and at each cl inic visit 
from Month 6 till Month 12 visit. PBC -40, PGI -S and PGI- C will be evaluated at each clinic 
visit over the whole study duration.  
The total duration of the study for each subject will be up to 60 weeks. The Screening  period 
will be up to 2 weeks, the run-in period will be 2 weeks, and  treatment period will be 52 
weeks . During the treatment period, subjects will be seen in the clinic every 3 months with an 
exception of first on treatment visit which will be performed after one month after initiatio n 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 38 of 94 of the study drug. Subjects will also return 2 weeks after Month 6 visit for blinded dose-
adjustment visit. In addition, s ubjects will have contact visits perform ed over phone or email 
every 12  weeks between on -site visits. At the end of 52 weeks of trea tment, subjects will be 
invited to participate in the long -term study (CB8025-31731) and continue their treatment 
with seladelpar; subjects on placebo will be switched to seladelpar. Subjects who do not want to continue seladelpar treatment beyond 52 weeks and decline long- term study participation 
will have a follow -up visit performed 4 weeks after the last dose of the study drug.  
Subjects will be asked to go through liver biopsy to evaluate PBC stage and activity . Subjects 
willing to undergo a procedure will have liver biopsy performed during the Run-In period. If 
liver biopsy was performed within 1 year prior to Day 1, Baseline liver biopsy can be waived. For these instances sites will attempt to collect biopsy material. The follow -up liver 
biopsy will be performed at least 3 years after initiation of treatment, during the long- term 
study (CB8025-31731).  
The study design implements safety criteria to monitor subjects with potential drug induced 
liver injury , muscle injury, renal injury and acute pancreati tis with actions to  either  stop the 
study drug, to interrupt the study drug, to down- titrate the study drug  or to investigate the 
case prior to actions with the study drug.  
If a subject terminates study participation at any point after Day 1, an Early Termination visit 
will be completed.  
The primary efficacy analysis will be a responder analysis (composite point) after 12 months of treatment with seladelpar. Th e study will be blinded for the study drug until the data base 
lock.  
Figure  3 Study Diagram – Clinical Study CB8025-31735 
 
 
7.1 Treatment and Allocation of Subjects  
Approximately 240 PBC patients will be enrolled into the study.  
Subjects will be  randomized to placebo, seladelpar 5/10 mg or seladelpar 10 mg in 1:1:1 ratio 
(approximately 80 subjects per group). Subject will be stratified by AP level (AP < 350 U/L 

CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 39 of 94 and ≥  350 U/L) and pruritus status (pruritus NRS < 4 and NRS ≥ 4). Subjects randomized to 
5/10 mg will start treatment with seladelpar d aily dose of 5 mg/day and after 6 months of 
treatment might up -titrate their  dose to 10 mg/day.  
7.2 Study Duration  
The study will be up to 60 weeks of duration and consists of the following periods: 
• Screening  period: up to 2 weeks  
• Run- In: 2 weeks  
• Treat ment Period : 52 weeks with an option to enter long- term s tudy (CB8025-31731) 
• Follow-up period: 4 weeks  (if not enrolled in long- term study)  
 
7.3 Study Outcome Measurements  
7.3.1 Primary M easures  
• Response on the composite endpoint of AP and total bilirubin at 12 months: 
o AP < 1.67 × ULN,  
o ≥ 15% decrease in AP, and 
o Total b ilirubin ≤ ULN  
• Assessment of treatment -emergent AEs  (TEAEs)  (National Cancer Institute [ NCI] 
Common Terminology Criteria for Adverse Events [ CTCAE ] Version 4.0), biochemistry 
and hematology 
 7.3.2 Key Secondary M easures 
• Proportion of patients with AP ≤ 1.0 × ULN at 12 months  
• Change from baseline in pruritus NRS  at 6 months 
 7.3.3 Other Secondary M easures   
• PBC -40 QoL at 6 and 12 months 
• PBC -40 QoL itch domain, and 5-D itch questionnaire 
• Response on the composite endpoint at 6 months 
• Proportion of subjects  with AP <1.67 × ULN and AP < 1.5 × ULN at 6 and 12 months 
• Proportion of subjects  with AP ≤  1.0 × ULN at 6 months 
• Change from baseline in pruritus NRS at 12 months 
• Absolute and relative changes in AP 
• Proportion of patients with PBC response criteria (Barcelona, Paris I and II, Toronto I 
and II , Rotterdam )  
• Change in UK-PBC and GLOBE risk score s 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 40 of 94 • Absolute and relative changes in ALT, AST, GGT, bilirubin (total, direct, and indirect), 
LDL-C, high density lipoprotein cholesterol (HDL- C), trigly cerides, and total cholesterol  
• The first occurrence of any of the following: 
o Overall death  
o Liver transplantation  
o MELD score ≥15  
o Uncontrolled ascites (diuretic resistant)  
o Hospitalization for new onset or recurrence of any of the following: 
 variceal bleeding  
 hepatic encephalopathy (as defined by a West Haven score ≥ 2)  
 spontaneous bacterial peritonitis (confirmed by culture from diagnostic 
paracentesis)  
o Hepatocellular carcinoma 
o Advanced  PBC as defined by the Rotterdam criteria (albumin below LLN AND total 
bilirubin above 1 × ULN)  
 
7.3.4 Exploratory M easures  
• C4 (7α -hydroxy-4- cholesten -3-one) 
• Fibroblast growth factor 19 (FGF19) 
• N-terminal type III collagen propeptide (Pro-C3) 
• Haptoglobin, f ibrinogen and hs-CRP, homocysteine, immunoglobulin M (IgM)  
• Autotaxin  
• Enhanced liver fibrosis (ELF) s core, f ibrosis-4 (FIB -4) score, Lok-Index, non- alcoholic 
fatty liver d isease (NAFLD) fibros is score  
• Liver elastography  (at selected centers ) 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 41 of 94 8 STUDY MEDICATIONS  
8.1 Clinical Supplies  
Investigational product (study drug) and UDCA will be supplied for the study.  
8.1.1 Investigational P roduct  (Study Drug), Dosage and Mode of A dministration  
Seladelpar  will be  supplied in a blinded fashion as 5 mg  and 10 mg capsules. Matching 
placebo will be provided. The study drug (seladelpar or placebo) will be administered orally, 
once daily  for the duration  of to 52 weeks. The subject will take 1 capsule every day, 
approxi mately at the same time each day.  
8.1.2 UDCA, Dosage and Mode of A dministration.  
The standard of care UDCA will be supplied  in an unblinded fashion. UDCA will be 
administered orally, one or multiple times per day at the  dose as close as possible to pre -
study dose and as recommended per investigator ’s clinical judgment. Pre -study UDCA will 
be switched to the study supply UDCA at the Screening visit. UDCA study supply will be 
provided for up to 56 weeks of duration (from the Screening visit through the Month 12 
visit). At the Week 52 visit, study supply UDCA will be switched to pre-study supply of 
UDCA.  
8.1.3 Packaging, Labeling and Shipping 
The Sponsor will provide the investigator  with packaged study drug and UDCA labeled in 
accordance with specific country regulatory  requirements.  The supplies will be shipped in 
accordance with the Pharmacy Manual . 
8.1.3.1 Dose Up -titration  
Subjects assigned to the seladelpar 5/10 mg group who are tolerating study drug  and are not 
responders based on composite endpoint according to  Month 6 la boratory result , will be up 
titrated from seladelpar 5 to 10 mg. Those patients initially assigned to placebo or 10 mg will 
not have their dose changed. Dose up-titration will occur 2 weeks after Month 6 period, when subjects will return to the clinic for dose titration visit. Dose up- titration will be performed in 
a blinded manner. 
8.1.3.2 Dose Down -titration  
Subjects who meet muscle safety monitoring criteria per Section 10.4.2 and eligible for the dose down- titration: subject who initially assigned to 10 mg will be down- titrated to 5 mg; 
subjects initially assigned to 5 mg, will be down -titrated to placebo. Subjects initially 
assigned to placebo will stay on placebo. Dose down -titration will be performed in a blinded 
manner.  
8.1.4 Accountability of Clinical Supplies   
The investigator or a designee will keep a record of the dates and amounts of study drug and 
UDCA re ceived , the amount dispensed to study subjects, and the amount returned from study 
subjects . 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 42 of 94 8.1.5 Replacement Study Drug  and UDCA  
Additional replacement study dr ug and UDCA will be available as required. All replacement 
shipments must be accounted for in the same manner as the initial drug  supply. 
8.1.6 Storage of Study Drug  and UDCA  
All supplies of study medication  and UDCA must be stored as defined in the Pharmacy 
Manual . 
8.2 Randomization 
Subjects will be randomized in a blinded manner to placebo or seladelpar in a 1:1:1 scheme 
(placebo: seladelpar 5/10mg: seladelpar 10 mg). In addition, randomized subjects will be stratified by AP level (AP < 350 U/L and ≥  350 U/L) and pruritus status (p ruritus NRS < 4 
and NRS ≥ 4). 
8.2.1 Randomization Procedure 
Randomization procedure will be performed centrally via interactive voice/web response 
system ( IXRS ) at Day 1 visit. A subject will be considered formally en rolled in the study at 
the time of randomization and begin study drug dosing.  
8.3 Emergency Unblinding  
In the event of a medical emergency, where knowledge of the subject’s treatment assignment is necessary per the medical judgment, the investigator  or the Sponsor can break the blind. 
The unblinding must be clearly justified and explained by a comment in the source documentation, along with the date on which the code was broken and the identity of the person authorizing the unblinding.  
8.4 Method of Administration and Compliance   
Study drug  will be dispensed on Day 1  and from Month 3 to Month 12 visits and will be 
taken orally once a day, according to the study schedule. UDCA will be dispensed at the  Screening visit and from Month 3 to Month 12 visits and will 
be taken orally as recommended per investigator clinical judgment. 
Compliance to the study drug and UDCA will be assessed through drug accountability  
evaluation. Study d rug and UDCA accountability will be evaluated at  Month 3 though Month 
12 visits  and Early Termination visits . 
8.5 Concomit ant Medications and Procedures   
The use of concomitant medications or procedures (defined below ), must be documented on 
the subject ’s electronic C ase Report F orm (eCRF). AEs related to the administration of these 
medications or procedures must also be documented on the appropriate section in the e CRF.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 43 of 94 8.5.1 Concomitant Medications  
A concomitant medication is any drug of substance other than study drug and UDCA, 
including over-the-counter medications, herbal medications and vitamin supplements, administere d durin g subjects’ participation in this trial.   
All subjects  will be instructed to remain on their current diet and lifestyle, including drinking 
habits, specifically alcoholic beverages, throughout the entire study. 
8.5.1.1 Allowed Concomitant M edication :  
Subjects will be allowed to receive required medication to treat new or existing medical 
conditions. 
8.5.1.2 Prohibited Concomitant M edication  
Use of OCA, fibrates (e.g. fenofibrate, bezafibrate), simvastatin, colchicine, methotrexate, azathioprine or long- term systemic corticosteroi ds (> 2 weeks) will be prohibited during the 
study. 
8.5.2 Concomitant P rocedures   
A concomitant procedure is any therapeutic intervention (e.g. surgery , biopsy, physical 
therapy) or diagnostic assessment (e.g. blood gas measurement, bacterial cultures) p erformed 
during subjects’ participation in this trial.  Subjects will be allowed to receive required 
procedures to treat new or existing medical conditions. 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 44 of 94 9 STUDY PROCEDURES  
9.1 Study Schedule  
The schedule of study pr ocedures is presented in  Table 1.  
The study for an individual subject consists of the following periods: 
• Screening Period : Week -4 to Week -2 
• Run- In: Week -2 to Day 1 
• Treatment Initiation : Day 1  
• Treatment Period: Day 1 through Month 12  
• Follow-up Period: 28 days after the last dose of the study drug (only applicable for subjects 
who are not willing to roll-over to long-term study (CB8025-31731). 
 
Visits, which occur within ± 3 days of the calculated date from Run-In period through the 
Month 1 visit and Dose ad justment visit and within ± 7 days of the calculated date from 
Month 3 through Month 12 will not be considered protocol violations. 
Additional visits may be schedule d to evaluat e an abnormal laboratory value or report ed AE. 
9.1.1 Screening  (Week -4 to Week -2)  
Subjects will r eview and sign the informed consent form (ICF) prior to any study- related 
procedures.  
Screening evaluations will be performed within 2 weeks prior to Run-In period.  The evaluations of eligibility will consist of:  
• Demographic information 
• Assessment of all  inclusion and exclusion criteria 
• Review of medical history, including PBC medical history , results of prior liver biopsy, 
liver elastography  (e.g., FibroScan), and alcohol consumption. The subject’s medical 
chart will be reviewed for evidence of other for ms of chronic liver disease as well as for 
HIV infection. 
• Documentation of prior and concomitant medication s including but not limited to 
previous exposure to UDCA, OCA as well as other medications taken for PBC and its 
symptoms  (including supplements and vitamins)  
• Vital signs (as described in Section 9.2.2 ). This w ill include temperature, heart rate, 
respiration rate and blood pressure  
• Height and w eight measurement s will be performed  
• Complete physical examination (as described in Section 9.2.1 ). This will include a full 
review of the following systems: general, skin, eyes, nose/sinuses, ears, mouth/throat, 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 45 of 94 neck, breasts, and respiratory, cardiac, gastrointestinal, peripheral va scular, genitourinary, 
musculoskeletal, neurologic, mental health, endocrine and hematologic 
• 12-lead electrocardiogram  (ECG) after at least 5 minutes  rest 
• Blood drawn for hemat ology, biochemistry , AMA , hepatitis B and hepatitis C  as outlined 
in Section  9.2.4 and Appendix A . If unexpected elevation of CK or INR is noted, re- test 
is allowed.  
• Women of child- bearing potential will have a  serum  pregnancy  test performed   
• Urine drug screen  
• E-dia ry training  
• Pruritus NRS  evaluation .  
• UDCA will be dispensed. Subjects will be instructed to switch their pre -study UDCA to 
study supply UDCA at the time of Screening. Subjects will be instructed to continue 
UDCA regimen (dose and frequency) as close as po ssible to regimen taken prior to the 
study participation and as recommended per investigator ’s clinical judgment.  
• Subjects who meet all inclusion criteria and do not meet any exclusion criteria will be 
invited for the Run-In visit.  
 
If an untoward event occurs at  any time after  the ICF is signed , it will be recorded as AE.  
Any laboratory abnormality deemed clinically significant by the investigator will be 
considered an AE. 
Subjects will be reminded of the following restrictions:  
• To comply with diet and lifestyle, including drinking habits 
• Not to use prohibited concomitant medications 
• Females of reproductive potential will be reminded to use at least one barrier 
contraceptive and a second effective birth control method during the study and for at least 
90 days after the last dose. 
• Male subjects who are sexually active with female partners of reproductive potential will 
be reminded to use barrier contraception and their female partners to use a second 
effective birth control method during the study and for at least 90 days after the last dose . 
 
9.1.2 Run-In (Week -2 to Day 1)  
Subjects who have been deemed eligible during the Screening  period will return for the Run-
In period.  
All subjects will have the following evaluations performed:  
• Documentation of AEs that occurred since the signing of the ICF 
• Documentation of medication (including supplements and vitamins) since the last visit 
• Vital signs  and weight (as described at Section 9.2.2)  
• Symptom- directed (brief)  physical exami nation (as described at Section 9.2.1)  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 46 of 94 • Blood drawn for hematology, biochemistry , and exploratory measures as outlined in 
Appendix A   
• Women of child- bearing potential will have a se rum pregnancy test performed  
• Back -up blood sample will be collected 
• E-diary will be dispensed. Re -training will be performed, if needed.  
• Pruritus NRS, 5-D itch, PBC-40 and PGI-S questionnaires will be performed via e-diary. 
The subject will be instructed  to use e-diary to evaluate pruritus NRS on a daily basis and 
5-D itch on a bi- weekly basis at approximately same time during the day from the Run- In 
visit through the first six month of study drug treatment. 
• UDCA accountability 
• Baseline liver biopsy: O nly subjects willing to under go the procedure to evaluate PBC 
stage and activity . PT and INR must be performed within 2 weeks prior to liver biopsy. If 
liver biopsy performed within 1 year from Day 1, baseline liver biopsy can be waived . 
For these instances  sites will attempt to collect biopsy material.  A follow up liver biopsy 
will be performed at least 3 years (± 3 months) of treatment during the long- term study 
(CB8025-31731). 
 
9.1.3 Treatment Period  
Day 1 (Randomization) Day 1 begins the treatment period and is the date against which all subsequent visits will be 
timed  with the exception of Dose Adjustment Visit and Follow Up period. At this visit 
subject s will be randomized into the study. A subject will be considered formally en rolled in 
the study at the time of randomization. On the scheduled clinic visit days, subjects will arrive 
to the clinic in the fasted state for laboratory assessments. If subjects forget to fast , this 
should be noted and the lab sample should still be collected.  
The following evaluations will be performed: 
• Randomization 
• Documentation of AEs that occurred since the signing of the ICF 
• Documentation of medication (including supplements and vitamins) since the last visit 
• Vital signs  and weight (as described at Section 9.2.2)   
• Complete  physical examination (as described at Section 9.2.1)  
• 12-lead ECG  after at least 5 minutes rest  
• Blood drawn for hematology, biochemistry , and exploratory measures (including fat-
soluble vitamins) as outlined in Appendix A   
• Back -up blood sample will be collected 
• Women of child- bearing potential will have a serum pregnancy  test performed . 
Additional on- treatment pregnancy testing may be performed at the investigator’s 
discretion or per local regulatory requirements. 
• PBC -40 and  PGI-S questionnaires via e-diary  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 47 of 94 • Pruritus NRS: review  of previously collected data. Subjects will be reminded to use e-
diary to evaluate pruritus on a daily basis  during the first s ix months of treatment. 
• 5-D Itch: review  of previously collected data. Subjects will be reminded to use e-diary to 
evaluate pruritus on a bi- weekly basis  up until the Month 6 visit. 
• Liver elastography (e.g, FibroScan): at selected sites  
• Study drug will be dispensed per the subject’s randomization with interactions to take 
orally once a day. The first dose of the study drug will be administered on site.  
• UDCA will be dispensed.  
• UDCA accountability will be performed.  
 
If a subject terminates study participation at any point after Day 1, an Early Termination visit 
will be completed.  
Month 1 
The visit will occur 4 weeks ± 3 days  after Day 1  and the following evaluations will be 
performed:  
• Documentation of AEs that occurred since the signing of the ICF 
• Documentation of concomitant medication (including supplements and vitamins) since 
the last visit  
• Vital signs and weight (as described at Section 9.2.2)  
• Symptom- directed (brief ) physical  examination  (as described at Section 9.2.1)  
• Blood drawn for hemato logy, biochemistry , and exploratory measures as outlined in 
Appendix A   
• Back -up blood sample will be collected 
• Women of child- bearing potential will have a serum  pregnancy blood test performed. 
Additional on- treatment pregnancy testing may be performed at the investigator’s 
discretion or per local regulatory requirements. 
• PBC -40, PGI-S and PGI-C questionnaires via e-diary  
• Pruritus NRS: review  of previously collected data . Subjects will be reminded to use e-
diary to evaluate pruritus on a daily basis  
• 5-D Itch: review  of previously collected data. Subjects will be reminded to use e-diary to 
evaluate pruritus on a bi- weekly basis.  
• Study drug and UDCA accountabi lity. 
 Month 3 The visit will occur 12 weeks ± 7 days  after Day 1 and the following evaluations will be 
performed:  
• Documentation of AEs that occurred since the signing of the ICF 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 48 of 94 • Documentation of concomitant medication (including supplements and vitamins) since 
the last visit  
• Vital signs and weight (as described at Section 9.2.2)  
• Symptom- directed (brief) physical examination (as described at Section 9.2.1)  
• Blood drawn for hematology, biochemistry, and exploratory measures as outlined in 
Appendix A   
• Back -up blood sample will be collected 
• Women of child- bearing potential will have a serum pregnancy test performed . 
Additional on- treatment pregnancy t esting may be performed at the investigator’s 
discretion or per local regulatory requirements. 
• PBC -40, PGI-S and PGI-C questionnaires via e-diary  
• Pruritus NRS: review  of previously collected data. Subjects will be reminded to use e-
diary to evaluate prurit us on a daily basis  
• 5-D Itch: review  of previously collected data. Subjects will be reminded to use e-diary to 
evaluate pruritus on a bi- weekly basis  
• Study drug and UDCA accountability 
• Study drug and UDCA dispense 
 
Contact 1 
The visit will occur 19 weeks ± 7 days  after Day 1 over the phone or by email contact and the 
following will be performed: 
• Documentation of AE s that occurred since the signing of the ICF 
• Documentation of concomitant medication (including supplements and vitamins) since 
the last visit  
• Compliance with study drug  
• Unscheduled visit scheduled, if deemed necessary by investigator 
 
Month 6 
The visit will occur 26 weeks ± 7 days  after Day 1 and the following evaluations will be 
performed:  
• Documentation of AEs that occurred since the signing of the ICF  
• Documentation of concomitant medication (including supplements and vitamins) since 
the last visit  
• Vital signs and weight (as described at Section 9.2.2)  
• Complete  physical examination (as described at Section 9.2.1)  
• 12-lead ECG after at least 5 minutes  rest  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 49 of 94 • Blood drawn for hematology, biochemistry, and exploratory measures as outlined in 
Appendix A   
• Back -up blood sample collection  
• Women of child -bearing potential will have a serum pregnancy test performed . 
Additional on- treatment pregnancy testing may be performed at the investigator’s 
discretion or per local regulatory requirements. 
• 5-D itch, PBC-40, PGI-S and PGI-C questionnaires via e-diary  
• Pruritus NRS: review  of previously collected data . Subjects will be instructed to use e-
diary on a monthly basis for 7 consecutive days each month through the Month 12 visit. 
• 5-D Itch: review  of previously collected data . Subjects will be instructed to evaluate 
pruritus via 5- D itch at the clinic visits only.  
• Liver elastography ( e.g., FibroScan) - a t the selected sites  
• Study drug and UDCA accountability 
• Study drug and UDCA dispense 
• Double-blind evaluation for dose up- titration will be performed. The d ouble-blind dose 
up-titration will be requested  if the following criteria are met: 
No safety 
concerns 
limiting up -
titration  AND  One of the following criteria:  
o AP ≥ 1.67 × ULN  
OR  
o < 15% decrease in AP comparing to baseline value  
OR 
o Total bilirubin > 1 × ULN  
 
Dose Adjustment Visit (2 weeks after Month 6 ± 3 days) To avoid unblinding, all subjects will be invited to Dose Adjustment visit. For subjects who 
have s afety concerns limiting up -titration, Dose Adjustment visit will still occur to evaluate 
subjects’ status. Dose Adjustment visit will occur 2 weeks after Month 6 visit and the following evaluations will be performed. Subjects will be instructed to not to take study drug at home prior to the clinic visit.  
• Documentation of AEs that occurred since the signing of the ICF 
• Documentation of concomitant medication (including supplements and vitamins) since 
the last visit  
• Vital signs and weight (as described at Section 9.2.2)  
• Brief symptom- directed physical examination (as described at Section 9.2.1)  
• Blood drawn for hematology, biochemistry, and exploratory measures as outlined in 
Appendix A   
• Study drug accountability  
• Additional assessments as determined by the Investigator  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 50 of 94 • Dose up- titration will be performed and s tudy drug will be dispensed in a blinded 
manner :  
o Subjects who meet the up -titration criteria: subjects on 5 mg will be dispensed 
seladelpar  10 mg; subjects on seladelpar  10 mg will be dispensed seladelpar 10 
mg, and subjects on placebo will be dispensed matching placebo. Subjects will 
immediately start dosing.   
o Subjects who do not meet the up- titration criteria will continue the initially 
assigned dose. 
 
Contact 2 The visit will occur  32 weeks ± 7 days  after Day 1 over the phone or by email contact and the 
following will be performed: 
• Documentation of AEs that occurred since the signing of the ICF 
• Documentation of concomitant medication (including supplements and vitamins) since 
the last visit  
• Compliance with study drug  
• Unscheduled visit scheduled, if deemed necessary by investigator  
 Month 9 The visit will occur 39 weeks ± 7 days  after Day 1 and the following evaluations will be 
performed:  
• Documentation of AEs that occurred since the signing of the ICF 
• Documentation of concomitant medication (including supplements and vitamins) since 
the last visit  
• Vital signs and weight (as described at Section 9.2.2)  
• Brief symptom- directed  physical examination (as described at Section 9.2.1)  
• Blood drawn for hematology, biochemistry, and exploratory measures as outlined in 
Appendix A   
• Back -up blood sample collection  
• Women of child- bearing potential will have a serum pregnancy test performed . 
Additional on- treatment pregnancy testing may be performed at the investigator’s 
discretion or per local regulator y requirements.  
• 5-D itch, PBC-40, PGI- C and PGI-S questionnaires via e-diary  
• Pruritus NRS: review  of previously collected data . Subjects will be instructed to continue 
to use e- diary on a monthly basis for 7 consecutive days each month through the Month 
12 visit. 
• Study drug and UDCA accountability 
• Study drug and UDCA dispense 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 51 of 94 Contact 3 
The visit will occur 45 weeks ± 7 days  after Day 1 over the phone or by email contact and the 
following will be performed: 
• Documentation of AEs that occurred since the signing of the ICF 
• Documentation of concomitant medication (including supplements and vitamins) since 
the last visit  
• Compliance with study drug  
• Unscheduled visit scheduled, if deemed necessary by investigator 
 
Month 12 
The visit will occur 52 weeks ± 7 days  after Day 1 and the following evaluations will be 
performed:  
• Documentation of AEs that occurred since the signing of the ICF 
• Documentation of concomitant medication (including supplements and vitamins) since 
the last visit  
• Vital signs and weight (as described  at Section 9.2.2)  
• Complete  physical examination (as described at Section 9.2.1)  
• 12-lead ECG after at least 5 minutes  rest  
• Blood drawn for hematology, biochemistry, and explor atory measures  (including fat-
soluble vitamins)  as outlined in Appendix A   
• Back -up blood sample collection  
• Women of child- bearing potential will have a serum pregnancy test performed . 
Additional on- treatment pregnancy testing may be performed at the investigator’s 
discretion or per local regulatory requirements. 
• 5-D itch, PBC-40, PGI-S and PGI-C questionnaires via e-diary  
• Pruritus NRS: review  of previously collected data. 
• E-diary will be collected  
• Liver elastography ( e.g., FibroScan ) - at the selected sites  
• Study drug and UDCA accountability 
Study supply of UDCA will be switched to pre-study supply of UDCA 
 At the end of the visit, subjects will be invited to participate in the long-t erm study 
(CB8025-31731). 
• Subjects who consent to participate in CB8025-31731 will have the Month 12 visit 
combined with the Day 1 visit of the CB8025-31731. Subjects on seladelpar will continue 
dosing ; subjects on placebo will initiate seladelpar (5 or 10 mg).  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 52 of 94 • Subjects who do not consent to participate in CB8025-31731 will stop study drug and 
enter the 4- week follow -up period.  
 
9.1.4 Post-Treatment Follow -Up 
The visit will occur four weeks (28 days ± 7 days ) after the last dose of the study drug. 
The following evaluations will be performed: 
• Documentat ion of AEs that occurred since the signing of the ICF 
• Documentation of concomitant medication (including supplements and vitamins) since 
the last visit  
• Vital signs and weight (as described at Section 9.2.2)  
• Complete  physical examination (as described at Section 9.2.1)  
• 12-lead ECG after at least 5 minutes  rest  
• Blood drawn for hematology, biochemistry, and exploratory measures as outlined in 
Appendix  A  
• Back -up blood sample collection  
• Women of child- bearing potential will have a serum pregnancy test performed  
 
This will be the subject’s last visit. Any clinically significant abnormalities should be 
followed up by the investigator, until resolution, or stabilization of those abnormalities.  
9.1.5 Early Termination Visit  
Subjects who discontinue participation in the study prematurely should return for an Early 
Termination Visit and the following evaluations should be performed: 
• Documentation of AEs that occurred since the signing of the ICF  
• Review and documentation of concomitant medication (including supplements and 
vitamins)  since the last visit  
• Vital signs and weight (as described at Section 9.2.2)  
• Complete physical  examination (as described at Section 9.2.1)  
• 12-lead ECG after at least 5 minutes rest 
• Blood drawn for hematology, biochemistry , and exploratory measures (including fat-
soluble vitamins) as outlined in Appendix A   
• Back -up blood sample will be collected 
• Women of reproductive status will have serum pregnancy test performed . Additional 
on-treatment pregnancy testing may be performed at the investigator’s discretion or per 
local regulat ory requirements. 
• Pruritus NRS, 5-D itch, PBC-40, PGI-S and PGI-C questionnaires via e-diary  
• Pruritus NRS: review  of previously collected data. 
• E-diary will be collected  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 53 of 94 • Liver elastography ( e.g., FibroScan ) - at the selected sites  
• Study drug and UDCA accou ntability  
• Study supply of UDCA will be switched to pre-study supply of UDCA 
 
Any clinically significant abnormalities should be followed up by the investigator until 
resolution or stabilization of those abnormalities.  
9.1.6 Unscheduled Visit   
Unscheduled visit m ust be scheduled if Safety Monitoring Criteria are met within the 
timeline outlined in Section 10.5. An unscheduled visit might be scheduled at any time 
during the study participation if deemed necessary per the investigator ’s clinical  judgement. 
At any Unscheduled Vis it the following evaluations will be performed:  
• Documentation of AE  that occurred since the signing of the ICF  
• Review and documentation of concomitant medication (including supplements and 
vitamins)  since the last visit  
• Symptom- directed (brief) physical examination (as described at Section 9.2.1)  
• Blood drawn for biochemistry and hematology  
• Additional assessments as determined by the investigator   
 
9.2 Study Asse ssments  
Supplementary study conduct information not mandated to be present in this protocol is 
provided in the accompanying Study Manual and other administrative guides, which will provide the study center personnel with administrative and detailed technic al information that 
does not impact subject safety.  
9.2.1 Medical History and Physical Examination  
A detailed medical history and PBC medical history will be taken at Screening .  
Complete physical examinations will be performed at Screening , Day 1, Month 6, Month 12, 
Follow-up visit, and Early Termination  visit (i f applicable) . These will include a full review 
of the following systems: general, skin, eyes, nose/sinuses, ears, mouth/throat, neck, breasts (optional, per clinical judgment only), respiratory , cardia c, gastrointestinal, peripheral 
vascular, genitourinary  (optional, per clinical judgment only), musculoskeletal, neurologic, 
mental health, endocrine and hematologic.  
Symptom- directed (brief) physical examination s will be performed  at Run-In, Month 1, 
Month 3, Dose Adjustment Visit, Month 9, and Unscheduled visits. Brief physical 
exam inations will be performed for a condition that warrants the exam as determined by the 
investigator . Subjects with platelet level above 500  × 10
3 µL on hematology panel will b e 
evaluated for thrombolytic events.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 54 of 94 Liver -related symptoms (e.g., nausea, vomiting, right upper quadrant pain, loss of appetite, 
dark urine, or jaundice) will be evaluated at each visit from Screening th rough Month 12 
visit, or unti l Follow-up visit or E arly Termination  (if applicable).  
Any clinically significant change  in physical examination findin gs that occur s after signing 
the ICF will be recorded as an AE .  
9.2.2 Vital Signs  and Weight/Height 
Vital sign measurements include temperature, heart rate, respi ratory rate, and blood pressure, 
recorded in the sitting position after at least 5 minutes rest.   
Vital signs and weight will be assessed on all in clinic visits , from Screening through Month 
12 visit, or unti l Follow-up visit or Early Termination  (if appl icable).  Height measurement 
will be performed only at Screening . 
Vital signs may be obtained more frequently if a condition develops that warrants additional 
monitoring. 
9.2.3 Electrocardiograms 
A 12 -lead ECG will be ob tained in supine position after at least 5 minutes  of rest at 
Screening, Day 1, Month 6, Month 12, and Follow-Up period or Early Termination  (if 
applicable).   
9.2.4 Laboratory Tests  
Laboratory testing (as described below) will be performed at  all clinic visits . Blood samples 
will be collected after at least an 8 -hour overnight fast and prior to dosing. If the  subject  
forgets to fast  or takes the study drug prior to the blood collection, the site will continue to 
draw labs.  
Hematology will be assessed at all visits.  
Biochemistry will be assessed at all vi sits.  
Exploratory Measures will be assessed at all onsite visits with the exception of Dose 
Adjustment Visit. At the Screening visit only AMA will be tested. Fat -soluble vitamins 
(vitamins A, D, E, and K) will be tested at Day 1 , Week 52 , and ET visit (if applicable)  only. 
Hepatitis B and C testing  will be assessed at Screening only . Women of child- bearing 
potential will have a serum pregnancy test performed at each clinic visit: Screening,  Run- In, 
Day 1, Month 1, from Month 3 through Month 12, and Follow-up visit or Early Termination 
(if applicable) . Additional on- treatment pregnancy testing may be performed at the 
investigator’s discretion or per local regulatory requirements. 
Urine drug screen will be assessed at Screening only.  
Laboratory  testing  will b e obtained as follows: 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 55 of 94 Biochemistry:  
AP, AST, ALT, GGT,  protein, albumin, total bilirubin, direct bilirubin, indirect bilirubin, 
bone- specific AP, aldolase, sodium, potassium, chloride, bicarbonate, blood urea nitrogen 
(BUN )/urea , creatinine , estimated glomerular filtration rate ( eGFR ), CK, venous blood 
glucose, lactate dehydrogenase ( LDH ), triglycerides , total cholesterol , HDL -C, and LDL-C, 
troponin I , lipase, and a mylase . 
Hematology:  
Erythrocyte c ount ( RBC ), hemoglobin, hematocrit, leukocyte count ( WBC ), WBC 
different ial (absolute and percentage), platelets , prothrombin time ( PT), and INR.  
PT and INR will also be performed locally at the Screening visit, Run -In, and during the 
treatment period if deemed necessary by the Investigator.  
Exploratory Measures: 
Anti-mitochondrial antibodies, autotaxin, IgM, fibronogen, FGF19, haptoglobin, hs- CRP, 
homocystein e, hyaluronic acid (HA),  procoll agen III amino terminal peptide,  Pro-C3,  tissue 
inhibitor of metalloproteinase 1 , C4 (7α -hydroxy -4-cholesten -3-one). 
Other Testing:  
HBsAg, HCV RNA; Vitamin A, Vitamin D, Vitamin E, and Vitamin K; serum pregnancy 
testing ( β-HCG)  
Back -Up Blood Sample:  
Blood samples collected during the study will be arch ived as back -up samples . These 
samples can be stored for up to 5 years following completion of the study and used to 
measure drug level, potential new biochemical markers, and/or to replace any missing or discarded samples.  
Urine Drug Screen:   
Amphetamine, THC (11-nor-9-carboxy- delta -9-THC), Cocaine, Opiates, and Phencyclidine. 
Sample collection, processing and handling details are provided in the Laboratory Manual. 
9.2.5 Liver Elastography  
Liver elastography ( e.g., FibroScan ) exam will be used to evaluate liver fibrosis through a 
noninvasive i maging technique. FibroScan is the most commonly used liver elastography 
method. It uses a modified ultrasound probe to measure the velocity of a shear wave. Cross-
sectional elastogram images will be created depicting the stiffness generated from the wave 
propagation information. FibroScan is considered to be a reliable, highly accurate, and precise method for assessing hepatic fibrosis.  Other liver elastography  techniques might 
include shear -wave elasticity imaging, acoustic radiation force impulse imagin ing, 
supersonic shear imaging, or magnetic resonance elastography. For sites when different liver elastography techniques are available, subjects must be evaluated using the same technique over the study duration. 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 56 of 94 Liver E lastography  Exam Schedule and Timing : Subjects will undergo three liver 
elastography  exams at centers when the test is available: Day 1, Month 6, Month 12 visits, 
and Early Termination  visit (i f applicable). Clinical sites will determine the logistics of 
scheduling the liver elastography  exam and complete within the study visit window.  
Liver E lastography  Exam Instructions:  Subjects will be instructed  to fast for 4 or more hours 
(if possible) prior to the scheduled liver elastography  exam ination  but will be allowed to take 
necessary medicatio ns and small quantities of water.  
Liver E lastography  Exam Analysis:  Local Reader will review and analyze scans.  
9.2.6 Liver Biopsy 
Subjects who are willing to evaluate their PBC stage and activity  will have liver biopsy 
performed during  Run- In period. If liver biopsy was performed within 1 year from Day 1, 
baseline liver biopsy can be waived. For these instances sites will attempt to collect biopsy 
material. This material might be used as a baseline comparison to liver biopsy that might be performed in at least 3 years (± 3 months) of treatment during the long -term study  
(CB8025-31731). 
Liver biopsies will generally be obtained from the right lobe of the liver, however, if the 
Baseline biopsy is obtained from the left lobe, then the follow-up liver biopsy (in CB8 025-
31731) must also be obtained from the left lobe. Biopsies should be performed using a 16G or larger biopsy instrument and samples should be at least 2.0 cm in length.  
Liver biopsy will be used to determine PBC stage and activity, using appropriate central reporting . 
Pre-Liver Biopsy Instructions : The subject must have PT, INR and platelets performed 
within 2 weeks prior to liver biopsy. Subjects will be instructed, if possible, to fast 6 to 8 hours prior to the scheduled liver biopsy.  
Liver Biopsy Anal ysis: Central reader will review and analyze the samples.  
9.2.7 Pruritus Numerical Rating Sc ale (NRS )  
Pruritus NRS will be used as a key secondary measure to evaluate pruritus in subjects with PBC .  
The test will be performed via e- diary on a daily basis from t he Run-In (Week - 2) visit and 
for the first six month of study drug treatment. After six month of treatment, pruritus NRS will be evaluated on a monthly basis over 7 consecutive days . See Appendix D  for details. 
Pruritus NRS data will be collected via e- diary.  
9.2.8 5-D I tch Scale 
The 5 -D itch scale will be used as a secondary measure for the multidimensional 
quantification of pruritus over time. The 5-D itch scale is a measure of itching that has been 
validated in patients with  chronic pruritus to detect changes over time. It is a brief, single 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 57 of 94 page, multiple choice or ‘check all boxes that apply’ form ( Elman , 2010) . See Appendix E  
for details.  
The test will be performed via e- diary on a bi-weekly basis from Run -In up up until the 
Month 6 visit,  and at each clinic visit from Month 6 through the Month 12 visit or Early 
Termination Visit (if applicable).  5-D itch data will be collected via e -diary.  
9.2.9 PBC -40 QoL  
The PBC -40 questionnaire will be used as a secondary measure to evaluate health -related 
QoL measures, specifically fatigue. PBC -40 is a disease- specific health related quality of life 
tool developed to specifically measure the psychom etric profile of PBC patients. It covers six 
domains relevant to PBC including cognitive, social, emotional function, fatigue, itch, and 
other symptoms ( Jacoby , 2005). See Appendi x F for details.  
It will be performed at each clinic visit from the Run-In period through the Month 12 visit, or Early Termination  Visit (if applicable).  The questionnaire will be evaluated by the site 
personnel and the investigator will react to any evidence of deterioration.  PBC -40 QoL data 
will be collected via e -diary.  
9.2.10 PGI-S and PGI- C  
The PGI -S and the PGI -C questionnaires will be used as an anchor scale to help interpret 
within -patient change in pruritus data collected via other pruritus questionnai res. See 
Appendix G  and Appendix H  for details.  
9.3 Dose Titration 
During the study participation subjects might go through dose titration for efficacy reasons. For subjects who have safety concerns lim iting up -titration, Dose Adjustment visit will still 
occur to evaluate subjects’ status. Subject will have a dose evaluation performed at the Month 6 visit to determine if dose up -titration is necessary. Dose evaluation will be done in a 
double-blind manne r. 
The double-blind dose up- titration will occur if the following criteria are met: 
No safety concerns 
limiting up -titration  AND  One of the following criteria:  
o AP ≥ 1.67 × upper limit of normal (ULN),  
 OR  
o < 15% decrease in AP comparing to baseline value, 
 OR 
o Total bilirubin > 1 × ULN  
 
Subjects who meet the criteria will receive the up -titrated dose at the Dose Adjustment visit 
(2 weeks after Month 6). Subjects on 5 mg will be up-titrated to 10 mg; subjects on 10 mg 
will continue 10 mg; and subjects on placebo will continue placebo.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 58 of 94 10 ADVERSE EVENTS  
10.1 General  
10.1.1 Definition  of Adverse Events  
An AE  is any medical occurrence in a subject administered a pharmaceutical  product in a 
clinical study , regardless of a causal relationship with this treatment. An AE can,  therefore, 
be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal  product, whether or 
not related to the medicinal product.  
An AE includes any condition (including a pre-existing condition) that: 1) was not present prior to  study treatment, but appeared or reappeared following initiation of study treatment, 
or 2) was pr esent  prior to study treatment, but worsened during study treatment. This would 
include any condition resulting from concomitant illnesses, reactions to concomitant medications, or progression of disease states. Pregnancy should be documented as an adverse event and should be reported to the clinical monitor and to the Sponsor immediately upon learning of the event. Pregnancies will be followed up through delivery or termination of the pregnancy. 
A treatment emergent adverse event ( TEAE) will be defined as any AE that newly appeared, 
increased in frequency, or worsened in severity after initiation of the study drug. For adverse 
event reporting purposes, UDCA is not considered as a study drug. 
10.1.2 Definition of Serious AEs  (SAEs)  
An SAE  is any medical occurrence that: 
• Results in death  
• Is life -threatening (was at risk of death) at the time of the event  
• Requires in -patient hospitalization or prolongation of an existing hospitalization 
• Results in persistent or significant disability/incapacity defined as a substantial disruption 
of a person’s ability to conduct normal life functions 
• Is a congenital anomaly/birth defect  
• Is an important medical event that, when based upon appropriate medical judgment, may 
jeopardize the subject and may require medical or surgical inter vention to prevent one of 
the outcomes listed above in the definition for an SAE. Examples of such events include 
allergic bronchospasm , requiring intensive treatment at an emergency room or at home, 
blood dyscrasias, convulsions that do not result in in-patient hospitalization, or the 
development of drug dependency or drug abuse 
 
10.1.3 AE Severity  
The severity of an AE will be graded from 1 to 5 according to Appendix C  and NCI C TCAE  
version 4.0 criteria (v4.03, 14 June 2010).  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 59 of 94 The CTCAE general guideline will be used to assess AE  severity. Not all g rades are 
appropriate for all AEs. Therefore, some AEs listed in the CTCAE ha ve fewer than five 
options for g rade selection.   
Grade  Clinical Description  
Grade 1  Mild; asymptomatic o r mild symptoms; clinical or diagnostic observations 
only; intervention not indicated.  
Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living.  
Grade 3  Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self -care activities of daily living.  
Grade 4  Life-threatening consequences; urgent intervention indicated.  
Grade 5  Deat h related to AE  
 
10.1.4 Adverse Event Outcome 
Subjects  will be followed until AEs have either resolved, returned to baseline status, or are 
deemed stable or commensurate with ongoing disease processes , per the Investigational 
judgment. 
One of the four outcomes listed below must be recorded: Resolved  – The subject  has fully recovered from the event with no residual effects 
observable or returned to baseline status. Resolved with sequelae – The subject  has recovered from the event with some residual 
effects observable.  
Ongoing – Effects of the event are still present, regardless of whether the effect is changing 
or stable and persistent. 
Fatal outcome (for serious adverse events only) 
10.1.5 Relationship to Study Drug  
The relationship or association of the AE  to a study dr ug will be characterized as 
“unrelated ”, “unlikely ”, “possible ”, “probably”, or “definite ”.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 60 of 94 Relationship  Attribution  Description  
Unrelated to the study 
drug Unrelated  The AE is clearly not related  to the study drug  
Unlikely  The AE is doubtfully  related  to the study drug  
Related to the study 
drug Possible  The AE maybe  related  to the study drug  
Probable  The AE is likely  related  to the study drug  
Definite  The AE is clearly  related  to the study drug  
 
10.1.6 Action Taken with Study Medication  
As a consequence of an AE, the action taken with study drug can be: 
• None: no changes were made to study drug administration or dose 
• Permanently discontinued: study drug was stopped and not restarted  
• Temporarily interrupted: dosing was temporarily interrupted or delayed due to the AE 
and restarted at the same dose 
• Temporarily interrupted: dosing was temporarily interrupted or delayed due to the AE 
and restarted at the decreased  dose 
• Not applicable : e.g. , in case the AE occurred after signing the ICF but before the 
administration of study drug was commenced  
 10.2 Recording, Reporting, and Follow- up of Adverse Events  
Details about the safety reporting process are presented in the Safety Reporting Plan.  
All AEs must be recorded by the investigator  in the e CRF , regardless of associ ation with  the 
use of the study treatment. An AE will be recorded any time after the time of signed ICF and 
captured until the last study visit.  
To avoid colloquial expressions, the AE should be reported in standard medical terminology. 
Whenever  possible, the AE should be evaluated and reported as a diagnosis rather than as 
individual signs or symptoms. If a definitive diagnosis is not possible, the individual signs and symptoms should be recorded.   
For each AE, the investigator or an adequately qualified designee will evaluate and report the onset, duration, severity, seriousness, and relationship to (association with) the study treatment, and indicate the action taken.  
Abnormal laboratory findings will be determined by review of all laboratory data collec ted 
on the subjects . At each visit, the investigator  is responsible for assuring that the subject  is 
questioned regarding all potential AE and concurrent illnesses.  
Any laboratory abnormalities deemed clinically significant by the investigator should be reported as an AE . A clinically significant abnormality is a confirmed abnormality that is 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 61 of 94 changed sufficiently from baseline, so that in the judgment of the investigator, a change in 
management is warranted. This alteration may include: monitoring the labor atory test further, 
initiating other diagnostic tests or procedures, or administering treatment. Whenever possible, the etiology of the abnormal findings will be documented in  the e CRF. Repeated, 
additional tests and/or other evaluations required to establish the significance and etiology of an abnormal result should be obtained when clinically indicated. 
Any clinically significant laboratory abnormalities that are either unexplained or considered 
treatment -related should be promptly reported to the Sponsor. Any additional relevant 
laboratory results obtained by the investigator during this study will be supplied to the Sponsor and recorded in the eCRF . 
10.2.1 SAE Reporting Process 
The Sponsor or designee is responsible for regulatory submissions and reporting to t he 
investigator s of SAEs including suspected unexpected serious adverse r eactions ( SUSARs ) 
per the International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) guidelines E2A and E6, and per the United States 21  
CFR § 312.32. Country specific regulatory requirements will be followed in accordance with local country regulations and guidelines. Independent Ethics Committees (IEC) will be notified of any SAE according to applicable regulations. 
Any SAE , including de ath due to any cause, that occurred  from the signing of ICF through, 
regardless of relationship to the study treatment, must be reported immediately  (no later than 
24 hours) by the investigator to the Sponsor’s representative ( safety vendor) using the SAE 
Report Form. Planned hospitalizations or procedures will not be considered as SAEs. The criteria for seriousness will be indicated on the SAE Report Form as defined in 
Section  10.1.2  
The outcome for the event will be l isted on the SAE Report Form as defined in 
Section  10.1.4. 
If additional information regarding a previously submitted SAE is obtained, a follow-up SAE must be sent to the Sponsor’s representative ( safety vendor ). 
The Sponsor and/or its designee will identify and  report to regulatory authorities within the 
required timeframe s, all serious and unexpected suspected adverse reaction s (SUSARs) and 
clinically important increase s in rate of serious suspected adverse reactions . 
SAEs  must be collected and reported by the investigator  for the whole period from the 
signing of ICF until the last study visit. If th e event of death occurs after the last study visit, 
the death will not have to be reported as a Serious Adverse Event.  
The in vestigator will document all available information regarding the SAE on the SAE 
form. The investigator should not wait to receive additional information to fully document 
the event before notifying the Sponsor’s representative of an SAE . The initial notification 
should include, as a minimum, sufficient information to permit identification of: 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 62 of 94 • Subject’s study number  
• Time a nd date of study drug administrations  
• Time and date of the start of the event and either the date and time of the resolution of 
the event  or a statement that the event is ongoing  
• A brief description of the event and counter- measures taken  
• Investigator’s opinion of the relationship of the event and the investigational product  
 
Follow-up report(s) should follow the initial repor t, using the S AE f orm in e CRF detailing 
relevant aspects of the adverse events in question. Where applicable, information from 
relevant hospital case records and autopsy reports should be obtained. All source information provided to the Sponsor must be appropriately anonymized.  
10.2.2 Follow-up of Reported AEs  
SAEs recorded during the study will be followed by the investigator until resolution  or 
stabilization.  
After the Follow-up Visit, n on-serious AEs should be followed up until they resolve or have 
failed to res olve, for a duration  determined by the investigator .  
Follow-up procedures will be determined by the nature of the event and the judgment of the investigator . 
10.3 Distribution of Responsibilities  
Details about the distribution of safety responsibilities are presented in the Safety Reporting Plan.  
10.4 Safety Monitoring Criteria and Withdrawal Criteria   
10.4.1 Liver Safety Monitoring   
Enrolled subjects  with the following lab abnormalities should be monitored closely and may 
interrupt study drug or discontinue study drug if criteria  are met:  
1. Elevation of ALT/AST 
Normal ALT/AST at baseline  
• ALT/AST > 5 × ULN and total b ilirubin ≤ 1 × ULN : Interrupt s tudy drug . Repeat 
AST, ALT, total bilirubin, and INR within 3 days and closely follow the subject 
(see Appendix B ). Study medication can be restarted only if a firm competing etiology is 
identified and liver tests return to baseline . 
• ALT/AST > 5 ULN and t otal bilirubin > 1 × ULN:  
o Subjects with normal total bilirubin at baseline: Stop study drug . Repeat AST, ALT, 
total bilirubin, and INR within 3 days and closely follow the subject (see 
Appendix B ). 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 63 of 94 o Subjects with elevated total bilirubin at baseline: 
 Total bilirubin > 1.5 × baseline: Stop study drug . Repeat AST, ALT, total 
bilirubin, and INR within 3 days and closely follow the subject (see 
Appendix B ). 
 Total b ilirubin ≤ 1.5 × baseline: Interrupt s tudy drug . Repeat AST, ALT, 
total bilirubin, and INR within 3 days and closely follow the subject ( see 
Appendix B ). Study medication can be restart ed only if a firm competing 
etiology is identified and liver tests return to baseline . 
 
Elevated ALT/AST at baseline: 
• ALT/AST > 3 × baseline AND INR  ≤ 1.5 × ULN AND no liver -related symptoms (e.g., 
nausea, vomiting, right upper quadrant pain, loss of appetite, dark urine, or jaundice): 
Continue study drug . Repeat AST, ALT, total bilirubin, and INR within 3 days. Closely 
follow the subject (see  Appendix B ). 
• ALT/AST > 3 × baseline AND INR  > 1.5 × ULN AND no liver -related sym ptoms (e.g., 
nausea, vomiting, right upper quadrant pain, loss of appetite, dark urine, or jaundice): 
Interrupt s tudy drug . Repeat AST, ALT, total bilirubin, and INR within 3 days and 
closely follow the subject ( see Appendix B ). Study drug can be restarted only if a firm 
competing etiology is identified and liver tests return to baseline.  
 
2. Liver -related symptoms (e.g., nausea, vomiting, right upper quadrant pain, loss of 
appetite, dark urine, or jaundice) AND ALT/AST > 3 × baseline (irrespective of 
baseline levels): Interrupt s tudy drug . Repeat AST, ALT, total bilirubin, and INR 
within 3 days. Closely follow the subject (see  Appendix B ). Study drug  can be 
restarted only if a firm competing  etiology is identified and liver tests return to 
baseline.  
3. Elevation of total bilirubin > 1.5 × baseline, regardless of ALT or AST levels, AND 
indicators of immunological reaction (e.g., rash, eosinophilia > 5%) OR liver- related 
symptoms (e.g., nausea, vomiting, right upper quadrant pain, loss of appetite, dark 
urine, or jaundice): Interrupt study drug . Repeat AST, ALT, total bilirubin, and 
INR within 3  days and closely follow the subject (see Appendix B ). Study drug can 
be restarted only if a firm competing etiology is identified and liver tests return to 
baseline. 
4. Hepatic decompensation (e.g., decompensated cirrhosis  with  gastro -esophageal 
variceal bleeding, ascites, or hepatic encephalopathy ) during the study : Stop s tudy 
drug  and closely follow the subject (see Appendix B ). 
5. Close monitoring of a subject is not possible (see Appendix B ): Stop study drug . 
 
10.4.2 Muscle Safety Monitoring  
I. CK > 5 × ULN with muscu loskeletal symptoms: Stop study drug . Repeat the test 
within 3 days. Follow the subject weekly until resolution or stabilization.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 64 of 94 II. CK > 5 × ULN without musculoskeletal symptoms: repeat the test within 3 days. If 
on repeat test CK is > 2.5 × ULN, stop study  drug . Follow the subject weekly until 
the event resolution or stabilization.  
III. CK > 2.5 × ULN and ≤ 5 × ULN regardless to musculoskeletal symptoms: repeat the 
test within 3 days. If the test is confirmed, study drug will be continued at a 
decreased dose.  For subjects on 5 mg, the study drug will be switched to placebo. 
 
10.4.3 Serum Creatinine Monitoring  
I. Serum creatinine > 2.0 × ULN: Stop study drug . The subject should be monitored 
weekly until resolution or stabilization.  
II. Serum Creatinine > 1.5 × ULN and ≤ 2.0 ×  ULN: I nterrupt study drug . Repeat the 
test within 3 days . If the test is confirmed and no alternative etiology is identified, 
stop study drug . If alternative etiology is identified, study drug may be restarted 
after serum creatinine returns to baseline values. The subject should be monitored 
weekly until event resolution.  
 10.4.4 Pancreatic Safety Monitoring  
I. Amylase > 3 × ULN and/or lipase > 3 × ULN without clinical symptoms of acute 
pancreatitis: repeat the test within 3 days. If the test confirms suspicion, in terrupt 
study drug . Abdominal imaging is to be performed to exclude an alternative cause 
for the event. Study drug might be restarted only if a firm competing etiology of acute 
pancreatitis is identified.  
II. Amylase > 3 × ULN and/or lipase > 3 × ULN with clin ical symptoms of acute 
pancreatitis: interrupt study drug . Repeat the test within 3 days. Abdominal 
imaging is to be performed to exclude an alternative cause for the event . Study drug 
might be restarted only if a firm competing etiology of acute pancreati tis is identified.  
 10.4.5 Additional Withdrawal Criteria and Replacement of Subjects 
Subjects may  be discontinued from the study for the following reasons: 
• Enrolled into  the study in violation of this protocol 
• Required the use of a prohibited concomitant medicat ion  
• The subject should be informed of new approved and available treatment to make an 
informed decision regarding continuation in the study. The availability of a new standard 
of care does not automatically terminate a subject from study participation.  
• Withdrawal of informed consent 
• At the discretion of the investigator for medical reasons  
• Female subjects who become pregnant  
• At the discretion of the investigator or Sponsor for noncompliance  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 65 of 94 • Significant protocol deviation  
• Administrative decision by the investigator or Sponsor or designee  
• Lost to follow-up 
 
The date the subject is withdrawn and the reason for discontinuation will be recorded in the 
eCRF.  
10.5 Precautions  
10.5.1 Pregnancy 
No specific human clinical studies have been performed to determine the reproductive and 
developmental toxicity of seladelpar.  
As a precaution, women of child bearing potential receiving study drug must use one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose. Sexual abstinence defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial an d the preferred and usual 
lifestyle of the subject.  
A second  effective birth control method may include:  
• combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation: 
o oral 
o intravaginal 
o transdermal  
• progestogen -only hormonal contraception associated with inhibition of ovulation: 
o oral 
o injectable  
o implantable  
• intrauterine device  
• intrauterine hormone- releasing system  
• bilateral tubal occlusion  
• vasectomized  partner  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 66 of 94 11 STUDY TERMINATION 
CymaBay Therapeutics, Inc. res erves the right to discontinue the study if it becomes aware of 
information concerning the quality, safety of the trial medication (based on recommendation 
from Medical Monitor), as well as other important information that may affect proper conduct of the trial. Should the study be discontinued by the Sponsor, then the investigator , 
IEC, and competent authorities  should be notified by the Sponsor or Sponsor’s delegate, in 
accordance with applicable regulatory regulations.  
The study may be prematurely termin ated by the Principal Investigator, due to specific 
clinical observations relating to safety concerns . If the Principal I nvestigator intends to 
prematurely  terminate the trial at his/her site , he/she must immediately inform the Sponsor on 
his/her intention  as well as of the reason s why . 
CymaBay Therapeutics, Inc. reserves the right to discontinue the study at any time for administrative reason s.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 67 of 94 12 DATA HANDLING  CONSIDERATIONS  
12.1 Processing of Electronic Case Report Forms  
The study will be  performed using elect ronic data capture ( EDC ). The investigator is 
responsible for prompt reporting of accurate, complete, and legible data in the e CRFs.  Any 
change or correction to the eCRF after saving must be accompanied by a reason for the 
change.  Corrections made after th e investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the investigator. The investigator  
should maintain a list of personnel authorized to enter data into the e CRF . The investigator 
will maintain a Site Delegation Personnel Log to document signatures and initials of all persons qualified and authorized by the investigator to make entries and/or corrections to the source documents. 
12.2 Database  
Data entry will be performed through username and password protecte d access to a secure 
database. All data will be entered using eCRFs. Internally developed programs for 
plausibility, consistency, and out-of- range data fields will supplement the review of the data. 
A 100% manual review of AEs, drug accountability and term ination summary data, will be 
performed by Data Management personnel. The Medical Dictionary for Regulatory Activities (MedDRA) coding thesaurus will be used to cl assify AEs and medical h istory, and 
the World Health Organization ( WHO) Drug classification w ill be used to code medications. 
Electronic CRFs will be available for review by the Clinical Research Associate (CRA) and Sponsor and Sponsor`s designee after completion by the site. The eCRFs will be monitored remotely and onsite by the Clinical Research  Organization ( CRO ) after documented training 
and in accordance with the monitoring plan. The CRA will review the eCRF data on a regular basis and post any queries for the site to complete prior to the scheduled onsite monitoring visits. Only those individuals who are qualified and authorized by the investigator to complete eCRFs will trained and receive passwords allowing eCRF completion.  
The completed eCRF must be electronically reviewed, signed, and dated by a qualified 
physician who is designated as Principal or Sub- investigator  for the study. The investigator 
must retain the original source documents. A final pdf of the eCRFs will be provided to the study site by the CRO or designee at the end of the study for archival purposes.  
An electronic audit trail system will be maintained within the eCRF to track all data changes 
in the database once the data have been saved initially into the system or electronically loaded . 
12.3 Data Discrepancies  
After all subjects complete the study and data discrepancies are resolved, protocol deviations during both enrollment and study execution will be reviewed. Significant protocol deviations and procedural discrepancies will be discussed. All data will be included in the safety analyses.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 68 of 94 13 STATISTICAL ANALYSES  
13.1 General Statisti cal Considerations 
Statistical analysis and generation of tables, figures, subject data listings, and statistical 
output will be performed using SAS Version 9.3.  
Descriptive statistics will be displayed to provide an overview of the study results. For 
categorical parameters, the number and percentage of subjects in each category will be 
presented. The denominator for percentages will be based on the number of subjects appropriate for analysis.  
Statistical tests of efficacy variables will be presented as 2 -sided p-values rounded to 4 
decimal places. P -values less than 0.0001 will be presented as “<0.0001” and p- values 
greater than 0.9999 will be presented as “>0.9999.” Statistical comparison will be performed at the 0.0500 level of significance . For continuous variables, display of descriptive statistics 
will generally include n (number of subjects), mean, standard deviation (SD), median, minimum, and maximum.  
13.2 Determination of Sample Siz e  
The placebo group responder rate is estimated at less than 15% ( Nevens, 2016) . The 
seladelpar 10  mg dose group responder rate is estimated at 40%. With the use of a 2-sided 
test of equality of binomial proportions based on Pearson chi- square test at the 5% level of 
significance, a sample size of 80 patients per group will provide greater than 90% power to 
detect a difference between the 10 mg seladelpar group and the placebo group. 
The key secondary efficacy analysis of normalization of AP is estimated to have a placebo 
response rate is of 5%. A 2 -sided test of equality of binomial proportions based on Pearson 
chi-square test at the 5% level of significance yields a sample size of 80 patients per group. 
This sample size provides more than 90% power to detect a difference of 30% between the 10 mg seladelpar and placebo groups.  
The key secondary efficacy analysis of change in pruritus NRS sample size calculation was  
based on a 2- sample 2 -sided t-test at the 5% alpha level. The standard deviation is 3 
(Lai, 2017). Under these assumptions, a total of 23 subjects per group provides ≥90% power 
to detect a treatment difference of ≥3 ( Lai, 2017) between 10 mg seladelpar and placebo 
groups. 
To account for a subject dropout rate of > 15%, the planned number of study subjects for an 
adequately powered study is 240 subjects, or 80 subjects per treatment group . 
Randomization will be centralize d to ensure adequate blinding of the study. 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 69 of 94 13.3 Analysis Sets 
13.3.1 Safety Set   
The safety set  is defined by any subject who receives at least one dose of study drug. 
Subjects will be included in the group based on treatment received, if this should differ from 
the treatment assignment. All safety analyses will be completed using the safety set . 
13.3.2 Intent to T reat A nalysis Set  (ITT)  
The ITT analysis set  is defined as any subject  randomized into the study.  
13.3.3 Modified Intent to Treat Analysis Set  
The Modified Intent to Treat (mITT) set  includes any subject who is randomized into the 
study and receives at least one dose of study drug . The mITT set  will be used for the primary 
efficacy analysis.   
13.3.4 Per Protocol (PP) Analysis Set  
The Per -Protocol (PP) set  includes any subject who is randomized into the study, receives at 
least one dose of study drug, has at least one post baseline AP and total bilirubin evaluation, and does not have a protocol violation that is deemed to impact the efficacy analysis. 
13.4 Analysis Time Points  
Baseline is defined as the arithmetic mean of multiple pre -treatment measurements 
(Screening, Run -In, Day 1, and UNS if applicable) preceding the first administration of study 
drug, or as the last measurement prior to the first administration of study drug if only single 
value is available.  
Unless otherwise noted, all references to Day 1 refer  to the day of st udy drug initiation for 
analytical purpose.  
Unless otherwise noted, all references to the last dose of study drug  refer to the last dose of 
study drug  taken across all study periods. 
The Last Visit for all assessments is the last non -missing assessment du ring the Treatment 
Period. All scheduled and unscheduled assessments within this time will be considered. Last 
Visit will be determined separately for each study procedure where Last Visit is mentioned within this document. 
13.5 Handling of Drop- Outs and Missin g Data 
Detailed descriptions of Handling Drop-Outs and Missing Data are contained in the SAP. All 
efforts will be made to prevent missing data from occurring.  
Sensitivity analyses will be performed on the primary efficacy endpoint using observed data only. The robustness of the primary analysis will be explored using several sensitivity analyses on a variety of patient populations including subjects who discontinue study drug.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 70 of 94 For responder analyses, any subject who does not provide an assessment at the specified time  
point for the defining of response will be considered a non-responder. 
For efficacy endpoints that utilized an analysis of covariance (ANCOVA) model, observed 
cases will serve as the primary analysis. The robustness of the primary analysis wil l be 
explored using several sensitivity analyses to assess the effect of missing data . Analysis will 
be conducted where missing data is imputed using a “responders,” last observation carried forward (LOCF) and “worst case” methodologies . For efficacy endpoints that utilized the 
mixed models repeated measures ( MMRM), no imputations will be made for missing values. 
The following additional sensitivities will be performed: 
• As responders 
• Same as primary analysis except based on the ITT Set.  
• Same as primary analysis except based on the PP Set.  
• Same as primary analysis except impute dropouts as non -responders in the seladelpar 
arm and as responders in the placebo arm (i.e. worst- case analysis).  
• Same as primary analysis except impute missing data using a pattern -mixture model 
(PMM) which considers different mechanisms for missing data.  
• Same as primary analysis except specify the proportion of patients achieving a 
decrease in AP as at least 10%, 20%, and 40%. 
• Using Medians instead of arithmetic means  for baseline va lues 
 
13.6 Disposition, Demographics and Baseline Characteristics  
The number of subjects screened, and the number and percentage of those subjects who were 
screen failures, broken down by primary reason for Screening  failure will be presented 
overall and repeated by stratification group.  
Demographic and baseline characteristics (medical histories, physical examinations, and 
concomitant medications) will be summarized using descriptive statistics for continuous variables and frequency distributions for discrete variables . Values will be summarized and 
listed using absolute values and percentages.  
Study participants that discontinued the study along with reasons for discontinuation will be 
summarized and listed.  
13.7 Efficacy Analysis 
Primary Efficacy Endpoint 
The p rimary efficacy analysis will be based on the following composite endpoint evaluated 
after 52 weeks of treatment:  
• AP < × 1.67 ULN,  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 71 of 94 • AP decrease of ≥ 15%, and 
• Total bilirubin ≤ ULN  
 
Treatment comparisons of the primary efficacy endpoint will be tested using a gateway 
method. A hierarchical “fixed -sequence” approach will be used to evaluate the primary 
endpoint as follows: 
1. The composite endpoint and seladelpar 10 mg vs placebo if negative stop 
2. If seladelpar 10 mg test is positive, that test the composite endpoint for seladelpar 5/10 
mg vs placebo; if negative stop  
This testing procedure maintains the overall Type I error for the primary efficacy endpoint at 
5%. Analyses for the composite endpoint will be completed using a Cochran–Mantel –
Haenszel (CMH) test stra tified by the randomization stratification factor (AP level < 350 U/L 
and ≥ 350 U/L)  and pruritis NRS < 4 and NRS ≥ 4 and will be conducted on the mITT 
population. If assumptions required for the CMH test including, but not limited to, small cell 
counts or all responses within a stratum are the same for both treatment groups (e.g., all responders within a stratum), additional data handling and analysis methodology will be used and described within the SAP. 
The fixed sequence approach is as follows: 
 
 
Notes : H1=Composite endpoint tested with 10 mg seladelpar vs. placebo, H 2=Composite 
endpoint tested with 5/10 mg seladelpar vs. placebo, H 3=AP Normalization tested with 10 
mg seladelpar vs. placebo, H 4=AP Normalization tested with 5/10 seladelpar vs. placebo, 
H5= Change from baseline in the weekly averaged peak pruritus NRS  over 6 months tested 
with 10 mg seladelpar vs. placebo, H 6= Change from baseline in the weekly averaged peak 
pruritus NRS  over 6 months tested with 5/10 mg seladelpar vs. placebo 
Statistical significance of the difference between placebo and seladelpar will be defined as a 
p-value ≤  0.05. Sensitivity analyses will be performed on the primary efficacy endpoint using 
  
        
      
      
  
   
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 72 of 94 observed data only. The CMH test will also be used for AP responder analyses, disease 
prognostic risk responder analyses, and subgroup analyses.  
Efficacy laboratory parameters  
Efficacy laboratory parameters will be analyzed using an ANCOVA model with absolute 
change and percent change from Baseline as the dependent variable includi ng treatment 
group and randomization stratification factor as fixed effects and Baseline as a covariate.  
Secondary endpoints  
The key secondary efficacy analysis for normalization of AP is a responder analysis and will be conducted in the mITT set using t he same approach specified for the primary efficacy 
analysis.  
Change from baseline in the weekly averaged peak pruritus NRS  over 6 months will be 
evaluated using ANCOVA with terms for treatment factor and baseline pruritis score as covariates. The analysis  will be limited to those subjects in the mITT analysis set with an 
NRS ≥ 4. The weekly pruritus score will be calculated by recording the daily pruritis score 
each day for seven days and then taking the median value of the seven days’ worth of daily recorded data. If any data are available for a given week, the available NRS results will be 
used for the calculation of the weekly median. If no NRS results are available in a given week, the median of the prior week will be used to impute those missing results using the last observation carried forward (LOCF) method.  
Sensitivity  analyses will be performed using the mITT population on all responder endpoints 
using a logistic regression model with response as the endpoint and treatment group and 
randomization strata as factors.  
Other Secondary endpoints will include the first occurrence of any of the following clinical events:  
o Overall death  
o Liver transplantation  
o MELD score ≥  15 
o Uncontrolled ascites (diuretic resistant)  
o Hospitalization for new onset or recurrence of any of the following: 
 variceal bleeding  
 hepatic encephalopathy (as d efined by a West Haven score ≥ 2)  
 spontaneous bacterial peritonitis (confirmed by culture from diagnostic 
paracentesis)  
o Hepatocellular carcinoma 
o Advanced PBC as defined by the Rotterdam criteria (low serum albumin AND 
total bilirubin above 1 × ULN)  
 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 73 of 94 Clinical events will be validated by a Critical Event Review Committee (CERC) composed 
of independent clinical experts familiar with hepatic diseases.  
Other secondary and exploratory analysis will be performed using ANCOVA similar to efficacy laboratory parameters where appropriate .  
Tables  and listing will be provided for all efficacy analysis and exploratory analysis and 
figures where appropriate.  
13.8 Safety Analysis 
All safety analyses will be based on the Safety population. TEAEs will be summarized by MedDRA  System Organ Class (SOC) and preferred term by severity and by causal 
relationship to seladelpar. The severity of TEAEs will be graded based on NCI CTCAE, Version 4.0. 
Safety laboratory parameters, liver fibrosis scores, vital signs, body weight, and body mas s 
index (BMI) values (absolute and change from baseline) will be summarized by treatment 
group using descriptive statistics at baseline and at each post -baseline visit.  
An overall summary of AEs will provide the overall summary of TEAEs and the numbers and percentages of subjects with at least 1 TEAE, with a serious TEAE, with a TEAE that led 
to permanent withdrawal of study medication, with a drug- related TEAE, with a severe 
TEAE, and with a drug-related serious TEAE. The number and percentage of subject discontinuations due to TEAEs, and the number and percentage of subjects with AEs leading to death (if applicable), will also be summarized.  
Descriptive statistics and change from baseline will be determined for each measure of 
laboratory tests, at each a ssessment. Abnormal laboratory values will be graded by the 
investigator as: “clinically significant” or “not clinically significant”, where available, and all laboratory values will be reported. Clinically significant abnormal laboratory values will be reported as AEs, after study treatment has been initiated. investigator s may repeat laboratory 
tests for any parameter that is abnormal and/or clinically significant.  
Tables and listings will be provided for all safety analys es. 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 74 of 94 14 DIRECT ACCESS TO SOURCE DATA/DOCUMENTS  
14.1 Study Monitoring  
14.1.1 Source Documents  
The investigator s and institution(s) will permit trial- related monitoring of the eCRF  data by 
CymaBay Therapeutics Inc. or their assignee by providing direct access to source data and/or 
documents. The  study moni tor will verify the CRFs against the source documentation. 
14.1.2 Case Report Forms 
Patients who have signed the ICF will be assigned a patient number and will have trial data entered into a CRF. CRF completion is important to the Medical Monitoring of the trial and should be completed promptly after each patient visit.  
14.1.3 Protocol Deviations 
Protocol deviations are not permitted, and protocol waivers will not be granted. Deviations to 
the protocol should be avoided, except when the investigator considers patient sa fety to be at 
risk if action is not taken. The Sponsor is to be notified of any protocol deviations that occur.  
Deviations from the will be noted in the source documentation, in the eCRF and a 
complementary database.  The Sponsor will assess any
 protocol deviation  and decide whether 
any of these  non- compliances  should be reported  to regulatory authorities as  a serious breach  
of ICH Good Clinical Practice ( GCP ) and the protocol.  
14.2 Audits and Inspections  
14.2.1 Trial Auditing  
Regulatory authorities, IEC , and/or CymaB ay Therapeutics Inc. or its designee(s) may 
request access to all source documents, e CRF  data, and other study documentation for on- site 
audit or inspection. Direct access to these documents must be guaranteed by the investigator, who must provide support at all time s for these activities.  
It is understood that all subject specific information is confidential and no documentation that can link study information to the specific subject will be collected  or retained by the Sponsor. 
14.2.2 Trail Monitoring  
A Sponsor representative will visit the site to initiate the study, prior to the first treatment of the first subject, and at agreed upon times throughout the study, including at the end of the study. Medication dispensing, and clinical drug supply records will be 100% verified at the study site by the study monitor. It is understood that all subject specific information is confidential and no documentation that can link study information to the specific subject will be collected or retained by the Sponsor.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 75 of 94 14.3 Ethics Co mmittees  
The investigators will provide I ECs with all information impacting the risk profile of the 
drug. The trial will not commence until written IEC approval for the protocol and ICF is 
received by the S ponsor. The investigator has the responsibility to conform to all of the local 
requirements for periodic updates and notification to the committee. 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 76 of 94 15 QUALITY CONTROL AND QUALITY ASSURANCE  
Clinical data  will be recorded in  eCRF . Data will be verified and confirmed by the 
investigator s. 
All data that will be used in the safety analyses and adverse events will be source documents 
verified by the monitors. Additionally, the Sponsor will conduct audit reviews of monitored eCRFs.  
A final audit of the electronic database against the final eCRF will be done. 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 77 of 94 16 ETHICS   
16.1 Ethics Review  
The protocols, ICFs, any information provided to the subject, recruitment advertisements, 
and any amendments to these items must be reviewed and approved by the IEC prior to the ir 
use in the trial.  
The study will not start before written ap proval by IEC(s) has been obtained and the local 
regulatory requirements have been complied with. The IEC must meet all the appropriate ICH requirements for composition, documentation, 
and operational procedures.  16.2 Ethical Conduct of the Study  
The study will be conducted in strict accordance with the Declaration of Helsinki, ICH GCP  
guidelines, applicable laws and regulations, and the procedures outlined in IEC approved 
version of this protocol.  
16.3 Written Informed Consent  
The subject must give consent to participate in the trial, only after having been fully informed 
by the investigator or a person designated by him/her of the nature, significance, and implications of the trial, as well as to the associated risks involved. Such meetings must be carried out on an individual basis and adapted to the educational background and previous knowledge of the subject. Participation in this meeting should be documented in the subject’s file. The subject must be allowed ample time to inquire about details and to decide whe ther 
or not to participate in the study. Written informed consent will be obtained for all subjects  
enrolled in the trial and before study related activities are performed on a subject . The 
process of obtaining written informed consent will be documented in the source documents of the subject . Only ICFs approved by the IEC will be used. 
The ICF must be personally dated and signed by both the investigator  and the subject. The  
original will be retained by the investigator and filed in the investigator’s Site File.  A copy of 
the original must be provided to the study subject. 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 78 of 94 17 RETENTION OF RECORDS  
All study related material , including source documents, e CRFs, competent authority, and I EC 
correspondence and analyses , and any other documentation required by applic able laws and 
regulations will be maintained for 1 5 years after completion of the study, or notification from 
the Sponsor that the data can be de stroyed, whichever comes first.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 79 of 94 18 PROTOCOL AMENDMENTS  
Any change or addition to this protocol will only be made when a protocol amendment has 
been written, approved, and signed by CymaBay Therapeutics, Inc. and the Principal Investigator before the change or addition can be considered effective. This amendment must also be submitted to the I EC for approval and, when necessary, competent authority  approval 
before implementation. Protocol amendments may affect consent forms of current and f uture 
subjects. CymaBay Therapeutics , Inc. will clearly specify when a protocol amendment 
includes safety, procedural, and/or effica cy information that will require specific ICF text 
changes.  
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 80 of 94 19 DISCLOSURE OF INFORMATION AND PUBLICATION POLICY 
Information concerning the investigational medication and patent application processes, 
scientific data or other pertinent information is confident ial and remains the property of 
CymaBay Therapeutics , Inc. The investigator may use this information for the purposes of 
the study only. It is understood by the investigator that CymaBay Therapeutics , Inc. will use 
information developed in this clinical study in connection with the development of the investigational medication and , therefore , may disclose it as required to other clinical 
investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the investigator  understands that he/she has an obligation to provide 
complete test results and all data developed during this study to the Sponsor.  
The investigator may not submit for publication or presentation the results of this study 
without first receiving written authorization from CymaBay Therapeutics, Inc. CymaBay Therapeutics , Inc. agrees that, before it publishes any results of the study, it shall provide the 
investigator  with at least 30 days for review of the pre-publication manuscript prior to the 
submission of the manuscript, to the publisher. 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 81 of 94 20 REFERENCES  
Bays HE , Schwartz S, Littlejohn T III, Kerzner B, Krauss RM, Karpf DB, et al.  MBX -8025, 
a novel peroxisome proliferator receptor- delta agonist: lipid and other metabolic effects in 
dyslipidemic overweight patients treated with and without atorvastatin.  J Clin Endocrinol 
Metab . 2011;96(9):2889-97. 
Barish GD , Narkar VA , Evans RM . PPAR delt a: a dagger in the heart of the metabolic 
syndrome. J Clin Invest. 2006;116(3):590-7. 
Choi YJ, Roberts BK, Wang X, Geaney JC, Naim S, Wojnoonski K, et al . Effects of the 
PPAR -δ agonist MBX -8025 on atherogenic dyslipidemia. Atherosclerosis. 2012;220(2):470-
6. Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, et al. Biochemical 
response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology . 2008;48(3):871-877. 
Elman S, Hynan LS, Gabriel V, and Mayo MJ. The 5-D Itch Scale: a new  measure of 
pruritus. Br J  Dermatol . 2010; 162(3):587- 593. 
Jacoby A, Rannard A, Buck D, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut. 2005;54(11): 1622-1629. 
Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, et al. Seladelpar (MBX -8025), A Selective PPAR- δ Agonist, in Patients with Primary Biliary Cholangitis with 
an Inadequate Response to Ursodeoxycholic Acid: A Double-blind, Randomised, Placebo-controlled, Phase 2, Proof-of-Concept Study. Lancet Gastroenterol Hepat ol. 2017;2(10):716-
726.  
Kaplan MM , Gershwin ME . Primary Biliary Cirrhosis. N Engl J  Med. 2005;353(12):1261-
1273.  Kumagi T , Heathcote EJ . Primary biliary cirrhosis. Orphanet J Rare Dis . 2008;3:1-17. 
Lai JW, Chen HC, Chou CY, Yen HR, Li TC, Sun MF, et al. Transformation of 5- D itch 
scale and numerical rating scale in chronic hemodialysis patients. BMC Nephrology. 
2017;18:56. 
Lindor K. Ursodeoxycholic Acid for the Treatment of Primary Biliary Cirrhosis . N Engl J 
Med. 2007;357(15):1524-1529.  Lindor KD. Primary biliary cirrhosis. Hepatology. 2009; 50(1): 291-308. 
Momah N, Lindor KD. Primary biliary cirrhosis in adults. Expert 2014. Expert Rev 
Gastroenterol Hepatol. Expert Rev Gastroenterol Hepatol.  2014;8(4):427-433. 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 82 of 94 Nevens F, Andreone P, Mazzella G, et al. A placebo -controlled trial of obeticholic acid in 
primary biliary cholangitis. N Engl J Med . 2016;18;375(7):631-643. 
Ocaliva Prescribing Information, Intercept Pharmaceuticals 2016. 
Poupon R E, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined 
analy sis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. 
Gastroenterology . 1997;113(3):884-890. 
Rishe E , Azarm A, Bergasa NV. Itch in Primary Biliary Cirrhosis: A Patients’ Perspective. 
Acta Derm Venereol . 2008;88:34–37.  
Selmi C, Affronti  A, Ferrari  L, and Invernizzi P. Immune- mediated bile duct injury: The case 
of primary biliary cirrhosis. World J Gastrointest Pathophysiol . 2010;1(4):118-128. 
 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 83 of 94 APPENDIX A – LABORATORY EVALUATIONS  
Biochemistry     
AP 
AST 
ALT 
GGT 
Protein 
Albumin  
Total Bilirubin  Direct  Bilirubin 
Indirect  Bilirubin  
Aldolase  
Sodium  
Potassium  
Chloride  Bicarbonate  
BUN/Urea  
Serum Creatinine  
eGFR  
CK 
Venous Glucose  
Troponin I  LDH  
TG 
Total Cholesterol 
HDL -C 
LDL -C 
Amylase  
Lipase  
Hematology  Exploratory 
Measures   Other Tests  
RBC  
Hemoglobin 
Hematocrit  
WBC  
WBC differentials 
(abs and %)  
Platelets  
PT/INR   AMA  
Autotoxin  
C4 
IgM 
Fibrinogen  
FGF19  
Haptoglobin 
hs-CRP  Homocysteine  
Hyaluronic acid (HA)  
Procollagen III amino 
terminal peptide  
Tissue inhibitor of 
metalloprote inase 1  
Pro-C3 
 Serum Pregnancy Test  
Back -up Sample   
HBsAg  (Screening only)  
HCV RNA  (Screening only)  
Vitamin A (D1, W52, ET only)  
Vitamin D (D1, W52, ET only)  
Vitamin E (D1, W52, ET only)  
Vitamin K (D1, W52, ET only)  
Urine Drug Screen (Screening 
only)  
 
 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 84 of 94 APPENDIX B – C LOSE OBSERVATION CRI TERIA  
The “close observation” will be performed on subjects meeting liver safety monitoring 
criteria per  Section 10.1.4. If “c lose observation” is not feasible, study drug must be stopped. 
1. Comprehensive Medical History and Health Status Review  
a. Provide detailed history of current liver- related symptoms (e.g., right upper 
quadrant pain or tenderness, nausea, vomiting, fatigue, loss of appetite, dark 
urine, or jaundice).  
b. Provide all current diagno ses, diseases, procedures, and symptoms 
c. Provide comprehensive medical history including prior diagnoses, procedures 
and symptoms 
d. Provide concomitant drug use, including: prescription medications, 
nonprescription medications, herbal supplements, dietary supplements, 
alcohol use, recreational drug use, special diets and exposure to environmental 
chemical agents  
e. Provide comprehensive medication and drug use history, including: 
nonprescription medications, herbal supplements, dietary supplements, 
alcohol use, recreational drug use, special diets and exposure to environmental 
chemical agents  
2. Laboratory Testing  
a. Repeat ALT, AST, Bilirubin (total), and PT/INR within 3 days  
b. Monitor the subject every 3 days until the lab abnormality stabilization  
c. After lab abnormality is stabilized, monitor the subject once a week until the 
event resolution 
3. Rule out the following diagnose s: 
a. Acute viral hepatitis types A, B, C, D and E  
b. Autoimmune or alcoholic hepatitis  
c. NASH 
d. Hypoxic/ischemic hepatopathy  
e. Biliary Tract Disease besides PB C 
 
 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 85 of 94 APPENDIX C – NATIONAL CANCER INSTITUTE COMMON TERMINOLOGY 
CRITERIA FOR ADVERSE  EVENTS (NCI CTCAE)  
The NCI CTCAE will be used to assess an AE severity.  
The NCI CTCAE will be provided as a separate document with the study protocol.  
The NCI CTCAE may al so be accessed here:  
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 86 of 94 APPENDIX D – PRURIT US NRS  
Rate the intensity of the worst itching  you experienced in the past 24 hours from no itching 
to worst possible itching by selecting a number.  
 
Itch Scale  
 0 1 2 3 4 5 6 7 8 9 10  
 
No 
itching           Worst 
imaginable 
itching   
 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 87 of 94 APPENDIX E – 5-D ITCH SCALE  
 

CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 91 of 94 APPENDIX G – PATIENT GLOBAL IM PRESSION OF SEVERITY  (PGI -S) 
Please choose the response below that best describes the severity of your pruritus over t he 
past week.  
o None 
o Mild  
o Moderate  
o Severe  
 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 92 of 94 APPENDIX H – PATIENT GLOBAL IM PRESSION OF CHANGE ( PGI-C) 
Please choose the response below that best describes the overall change in your pruritus since 
you started taking the study drug.  
o Very Much Better  
o Moderatel y Better  
o A little bit better  
o No change  
o A little worse  
o Moderate Worse  
o Very much worse  
 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 93 of 94 APPENDIX I – NORMAL RANGES  FOR SAFETY LABORATORY PARAMETERS  
BIOCHEM ISTRY  Conventional Units  SI Units  
AP 37-116 U/L  37-116 U/L  
Albumin  3.5-5.5 g/dL  35-55 g/L  
ALT  6-41 U/L 6-41 U/L  
AST  9-34 U/L  9-34 U/L  
GGT  Female  : 7-38 U/L  
Male  : 11-52 U/L  Female  : 7-38 U/L  
Male  : 11-52 U/L  
Protein  6.0-8.0 g/dL  60-80 g/L  
Total Bilirubin  0.10 – 1.10 mg/dL  1.7-18.8 umol/L  
Direct  Bilirubin  0.00-0.20 mg/dL  0.0-3.4 umol/L  
Indirect  Bilirubin  0.10- 1.00 mg/dL  1.7-17.1 umol/L  
Aldolase  <7.7 U/L  <7.7 U/L  
Sodium  134-144 mmol/L  134-144 mmol/L  
Potassium  3.5-5.1 mmol/L  3.5-5.1 mmol/L  
Chloride  95-110 mmol/L  95-110 mmol/L  
Bicarbonate  21-33 mmol/L  21-33 mmol/L  
BUN/Urea  5-22 mg/dL  1.79-7.85 mmol/L  
Serum Creatinine  Female  : 0.49 -1.12 mg/dL  
Male  : 0.62 -1.44 mg/dL  Female  : 43-99 umol/L  
Male  : 55-127 umol/L  
CK 25-210 U/L  25-210 U/L  
Venous Glucose  60-115 mg/dL  3.3-6.4 mmol/L  
Troponin I  <0.3 ng/mL  <0.3 ug/L  
LDH  113-226 U/L  113-226 U/L  
TG 50-150 mg/dL  0.57-1.70 mmol/L  
Total Cholesterol  100-200 mg/dL  2.59-5.18 mmol/L  
HDL -C 35-60 mg/dL  0.91-1.55 mmol/L  
LDL -C 50-130 mg/dL  1.30-3.37 mmol/L  
Amylase  22-123 U/L  22-123U/L  
Lipase  11-82 U/L  11-82 U/L  
HEMATOLOGY    
RBC  Female  : 3.90 – 5.40 10^6/uL  
Male  :  4.30 – 6.00 10^6/uL  Female  : 3.90 – 5.40 10^12/L  
Male  :  4.30 – 6.00 10^12/L  
Hemoglobin  Female  : 12.0 -16.0 g/dL  
Male  :  13.6 -18.0 g/dL  Female  : 120 -160 g/L  
Male  :  136 -180 g/L  
Hematocrit  Female  : 35-45% 
Male  :  40-52% Female  : 0.35 -0.45 
Male  : 0.4-0.52 
WBC  3.5-11.0 10^3/uL  3.5-11.0 10^9/L  
Neutrophils, abs  1.0-8.0 10^3/uL  1.0-8.0 10^9/L  
Lymphocytes, abs  1.0-5.0 10^3/uL  1.0-5.0 10^9/L  
Eosinophils, abs  0.0-0.8 10^3/uL  0.0-0.8 10^9/L  
Monocytes, abs  0.0-1.0 10^3/uL  0.0-1.0 10^9/L  
Neutrophils, %  40.0-80.0 %  40.0-80.0 %  
Lymphocytes, %  15.0-45.0 %  15.0-45.0 %  
Eosinophils, %  0.0-10.0 %  0.0-10.0 %  
Monocytes, %  0.0-12.0 %  0.0-12.0 %  
Platelets  140-400 10^3/uL  140-400 10^9/L  
PT Reagent specific ranges  Reagent specific ranges  
INR 0.8-1.2 0.8-1.2 
OTHER    
Pregnancy test (β -HCG)  Female  : 0-5 IU/L  Female  : 0-5 IU/L  
Vitamin A  24-128 ug/dL  24-128 ug/dL  
Vitamin D  30-80 ng/mL  75.0-200.0 nmol/L  
Vitamin E  0.51-2.88 mg/dL  0.51-2.88 mg/dL  
Vitamin K  0.22-4.88 nmol/L  0.22-4.88 nmol/L  
HBsAg  Non-reactive  Non-reactive  
HCV RNA  Not Detected  Not Detected  
 
CymaBay Therapeutics, Inc   Protocol CB8025- 31735  
Protocol Version 1.0, 3 -JUL-2018  CONFIDENT IAL  Page 94 of 94 APPENDIX J  – INVESTIGATOR’S PROTOCOL SIGNATURE  PAGE  
CB8025 -31735 
A 52-week, placebo -controlled, randomized, Phase 3 study to evaluate the safety and 
efficacy of seladelpar  in subjects with Primary Biliary Chola ngitis (PBC) and an inadequate 
response to or an intolerance to ursodeoxycholic acid (UDCA)  
 
PROTOCOL VERSION NUMBER:   Version 1.0  
DATE OF PROT OCOL:    3- JUL-2018 
 
SPONSOR:  CymaBay Therapeutics, Inc. 
7575 Gateway Blvd, Suite 110 
Newark, CA 94560 
United St ates of America  
I have read all pages of this clinical study protocol for which CymaBay Therapeutics , Inc. is 
the Sponsor. I agree to conduct the study as outlined in the protocol and to comply with all 
the terms and conditions set out therein. I confirm t hat I will conduct the study in accordance 
with ICH GCP guidelines  and the provisions of Declaration of Helsinki. I will also ensure 
that sub- investigator (s) and other relevant members of my staff have access to copies of this 
protocol, and the ICH GCP gui delines  and Declaration of Helsinki, to enable them to work in 
accordance with the provisions of these documents. 
 
Investigator :   
Printed Name:    
Signature:    
Date 
(DD/MMM/YYYY):    
Site Address:    
   
   
 